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 While a number of PEGylated proteins have been studied for injectible 
applications and reviewers have used this data to speculate possible oral delivery 
improvements, a detailed investigation of PEGylated insulin for oral delivery and 
the development of an optimized pH-sensitive carrier for PEGylated insulin 
conjugates had yet to be accomplished. 
  In order to proceed with oral delivery study, improvements in yield, with 
respect to previous PEGylation methods were necessary to enable the 
completion of high throughput drug delivery studies.  Subsequently, a reaction 
scheme for the covalent attachment of PEG to insulin using nitrophenyl 
carbonate-PEG was developed. It was demonstrated that this reaction occurred 
at a 1:1 ratio and was site specific at the B29Lys position.  
A P(MAA-g-EG) hydrogel carrier was developed  to optimize loading and 
release behavior for PEGylated insulin. It was demonstrated that the density and 
 vii 
length of polymer grafts affected both loading and release behavior of PEGylated 
insulin.  The best performing grafted polymers had a 3:1 methacrylic acid: 
ethylene glycol  (MAA:EG) ratio and achieved loading efficiencies from 96% to 
nearly 100%.   With respect to release, polymer particles containing fewer, but 
longer grafts shown to release faster than polymers with shorter grafts with the 
same MAA:EG ratio. 
      Finally, the effects of PEGylation on intestinal absorption was investigated 
using an intestinal epithelial model as well as a rat model.  It was demonstrated 
that PEGylated insulin in the presence of P(MAA-g-EG) microparticles did not 
significantly alter the tight junctions over unmodified insulin. However, the 
conjugate permeabilities across the membrane were reduced. The 
pharmacological availability (PA) was then verified by injecting the insulin 
conjugates subcutaneously in fasted Sprague-Dawley rats.  It was determined 
that PEG 1000 insulin (1KPI) had a PA roughly equivalent to insulin, while it was 
reduced by 59% for 2KPI and by 81% for 5KPI. The effectiveness of utilizing 
PEGylated insulin as an oral drug delivery candidate was evaluated with a closed 
loop intestinal study, in which PEGylated insulin or insulin in solution was 
delivered directly to the jejunum.  It was shown that 1KPI and insulin performed 
identically; with a pharmacological availability of 0.56%.  2KPI, however improved 
the pharmacological availability of insulin by 2.8 times.  These results 
 viii 
demonstrate that PEGylation holds promise for improving the oral delivery of 
proteins. 
 ix 
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 1 
 
CHAPTER 1 
INTRODUCTION 
 
Diabetes is a chronic metabolic disease characterized by hyperglycemia 
due to decreased insulin secretion (Type 1) or decreased insulin action (Type 2).  
Type 1 diabetes is also referred to as juvenile onset diabetes as it is primarily 
diagnosed in children and young adults.  These patients require insulin 
replacement therapy in order to control insulin levels. In contrast, Type 2 diabetes 
usually begins in adulthood and can be controlled through diet and drugs that 
improve insulin action, in addition to insulin replacement therapy.  
Untreated hyperglycemia can cause a loss of glucose in the urine (100 
g/day), severe dehydration, and finally tissue injury.  When blood glucose levels 
are poorly controlled over long time periods, blood vessels begin to undergo 
structural changes that result in inadequate blood supply to the tissues. Patients 
with vascular damage are at increased risk for heart attack, stroke, kidney 
disease, blindness, and gangrene of the limbs [1].   In severe cases, diabetes 
can cause a shift from carbohydrate metabolism to fat metabolism. This shift 
results in an increase in the release of keto acids, causing 
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a drop in blood pH.  A reduction in blood pH can quickly lead to excessive urine 
formation and, subsequently, severe dehydration. Severely dehydrated patients 
can rapidly fall into a coma and die unless they are treated with large amounts of 
insulin [1].  Additionally, elevated glucose levels can damage the peripheral 
nerves, which may result in impaired bladder control and reflexes, as well as 
dampened sensation [1].   
Diabetes is a high-impact problem as it affects nearly 120 million people 
worldwide, and according to a survey conducted by the World Health 
Organization in 2005, is predicted to rise to 300 million by the year 2030.  This 
disease also has a high price tag; 1 in 7 US dollars are spent on behalf of a 
patient with diabetes. On average, each patient spends 2.3 times more on 
healthcare than a patient without diabetes, which adds up to an average of 
$6,649 per year in treatment directly related to diabetes.   [2, 3].   
In both types of diabetes, blood glucose measurements should be 
monitored throughout the day for the purpose of determining dosage.  This is 
especially important for severe diabetics, resulting in as many as 5 injections 
each day. Patients often fail to follow the regimen necessary to maintain 
desirable blood glucose levels which can quickly lead to any of the issues 
described above.  In addition, the subcutaneous injection of insulin results in 
peripheral hyperinsulinemia, which in 30% of insulin dependent patients results in 
fat atrophy.  Pump delivery reduces peripheral hyperinsulinemia by administering 
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the glucose in smaller doses over time.  One issue with this system is that a 
needle must remain in the skin, compromising the bodyʼs protective barrier. As 
such, the needle site is a common location for infection. 
Drug companies have long since considered oral delivery to be the most 
desirable form of drug delivery.  An oral insulin delivery system is expected to 
lead to an increase in patient compliance, which would subsequently lead to 
decreased hyperglycemia.  Fewer hyperglycemic incidents will result in fewer 
diabetic related complications, and ultimately a better quality of life.  From a 
physiological standpoint, the insulin must pass through the liver when absorbed 
through the digestive tract.  As a large percentage of insulin degradation takes 
place in the liver, the liver will have some control over the amount of insulin 
released into the blood stream. 
The ability to deliver insulin in this manner is limited by the harsh 
environment of the GI tract, the decreased ability of the insulin to cross the 
intestinal epithelium due to its large size (5808 da), and the ability to maintain 
drug stability and bioactivity. 
To overcome these obstacles, poly(methyacrylic acid-g-ethylene glycol) 
(P(MAA-g-EG) anionic hydrogels have been developed that remain collapsed in 
the stomach and expand when they reach the small intestine.  This hydrogel 
effectively protects the protein from acid hydrolysis in the stomach and allows it 
to be released in the small intestine where it is absorbed. In order to ensure that 
 3 
insulin is increased near the site of absorption, lectins have been conjugated to 
the surface of these particles to enable mucoadhesion as well as transport into 
the cell.  Work done by Kristy Wood showed that the conjugation of lectin to 
P(MAA-g-EG) microparticles led to a bioavailability of 11.9% [4]. Although this is 
a great improvement over previously reported numbers (2.44%), additional 
improvements are necessary before this method is commercially feasible [5].  
Thus, other potential improvements are being tested. A number of molecules are 
being co-delivered or conjugated to the insulin molecule.  These include 
transporters, codelivery with tannic acid to inhibit enzymes, and PEGylation to 
improve stability, residence time and reduce degradation.  Finally, new polymer 
formulations are being developed that to further improve drug delivery. 
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CHAPTER 2 
BACKGROUND 
 
2.1. Anatomy and Physiology 
2.1.1. The Pancreas, Insulin, and Blood Glucose Regulation 
The pancreas is a unique organ because it serves both an exocrine and 
endocrine function. Composed primarily of acinar cells, it produces roughly 1200 
to 1500 mL of pancreatic juice per day. Pancreatic juice is a high pH mixture that 
consists primarily of water, enzymes, and electrolytes [1]. Enzymes include 
trypsinogen, which is activated by enterokinase to form trypsin, carboxypeptitase, 
and chymotrypsin. The pancreas also produces amylases, lipases, and 
proteases.  Islets of Langerhans, responsible for the endocrine function of the 
pancreas, are dispersed between the aciner cells.  This structure contains beta 
cells that sense and secrete insulin [1].  
Insulin is a hormone that causes most body cells to take up glucose from 
the blood and store it as glycogen in fat cells, muscles or the liver.  When insulin 
is low, and glycogen is not taken up in sufficient quantities, the body begins to 
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use fat as an energy source.  Insulin is also a component of amino acid uptake 
as well as a number of important anabolic processes. 
 The pancreas is stimulated to produce and release insulin when the 
autonomic nervous system senses food intake as well as when proteins are 
digested or glucose is found in the blood.  Carbohydrates and sugared goods are 
the main sources of glucose in the body [2]. Glucose enters pancreatic β cells 
causing the release of insulin.  Insulin decreases glucose production in the liver 
and stimulates glucose uptake, utilization and storage.  Fat cells release free fatty 
acids that reduce glucose uptake in the cells and increase glucose production in 
the liver.  The fat cell also secretes adipokines which regulate food intake, energy 
expenditure and insulin sensitivity [3]. 
Typically, insulin manufacture starts by creating preproinsulin in the 
ribosomes. The preproinsulin is converted to proinsulin, and is moved to the 
secretory granules of the Golgi complex. When stimulated, in this case by 
acidification, proinsulin is folded upon itself and a central portion is cleaved with 
prohormone convertases PC1 and PC2.  This result is C-peptide and the α and β 
chain of insulin.  Finally, carboxypeptidase E creates mature insulin by causing 
the formation of disulfide bonds  [2, 4].   
 The most well understood and presumably the most important insulin 
release pathway is in response to blood glucose levels.  Insulin is signaled to 
release from the vesicle with the entry of glucose into the β cell via GLUT2 
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facilitated diffusion.  This receptor only exists in the pancreas, liver, kidneys and 
some neurons in the brain and is unique in that it does not require insulin in order 
to uptake glucose. Once inside the cell, the glucose molecule is phosphorolated 
and is no longer able to exit the cell.  Glucose undergoes glycolysis to form ATP.  
ATP instigates the opening of the calcium channels, which causes the cell to 
depolarize.  An increase in calcium concentration triggers the secretory granules 
of the β cells to release insulin into the bloodstream [2]. 
 When released into the bloodstream, in order to produce a metabolic 
effect, insulin binds to the insulin receptor. Once this happens, GLUT4, the 
typical insulin-requiring receptor that allows glucose to enter the cells, moves into 
the plasma membrane and allows glucose to enter the cell.  Once glucose goes 
into the cell, it is phosphorolated to prevent the molecule from leaving the cell.  
Glucose goes through glycolysis to form ATP, which is stored inside as an 
energy source.  Although all body cells must go through this process to produce 
ATP, this process has the highest throughput in liver and muscle cells [2].  This 
process is depicted in Figure 2.1.  
The insulin molecule is a 51 amino acid protein consisting of two 
polypeptide chains (A and B) linked with two disulfide bonds. The complete 
struture of insulin is shown in Figure 2.2.  At a pH of 4-8, the insulin monomer 
assembles to dimmers, and if the concentration is sufficiently high (1.15 g/mol) or 
zinc ions are present, further to hexamers [5].  Insulin hexamers have been 
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shown to degrade up to six times faster than their monomeric counterpart in the 
presence of bile salts [6].  Insulin may also aggregate linearly, forming insoluble 
fibrils.  It is believed that the fibrils form when monomers oligomerize [7].  Once 
oligmers reach the critical threshold concentration and the solution is agitated, 
fibrils form.  Fibril formation also increases with increasing insulin concentration, 
increased agitation, and decreasing pH.  Fibrils have been shown to elicit an 
immunogenic response and are not biologically active [7].  The immune response 
causes the body to rapidly eliminate insulin from the patientʼs circulation in the 
form of immune complexes.  Repeated administration may lead to allergic and 
even anaphylactic symptoms [8]. 
Insulin has three amino acids that are available for amine functionalization: 
A1-Glycine (A1Gly), B1-Phenylalanine (B1Phe), and B29-Lysine (B29Lys) [8].  
The locations of these amines with respect to the amino acid structure are 
highlighted in red in Figure 2.2.     
It has been reported that the functionalization of insulin at the A1Gly 
position can lead to a decreased bioactivity of insulin [9]. As a result, insulin 
modification typically occurs at B1Phe or B29Lys positions [10].  The pKa of both 
A1Gly and B1Phe is approximately 7.5-8.0 and the pKa of lysine is approximately 
10 [11]. In reactions, if the pH is more than 2 units below the pKa of the lysine 
residue, most of the lysine residues will not react [12]. 
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About 50% of the insulin is degraded in the liver and a significant 
percentage of the remaining insulin reenters the circulation. A five-compartment 
model was used to predict the mean residence time of endogenously secreted 
insulin. The model predicted that the mean residence time was 71 minutes, with 
62 minutes bound to liver receptors, 6 minutes bound to receptors of other tissue 
types such as muscle, and 3 minutes in the blood [13]. This model predicted that 
80% of the total insulin in the body was bound to liver receptors at any given time 
[13]. Insulin primarily interacts with the Kupher cells in the liver. While the exact 
mechanism is unknown, the uptake occurs through receptor-mediated 
endocytosis and pinocytosis.   About half the insulin that is uptaken by Kupher 
cells is never released from the cell, as it is degraded within cell.  The kidneys 
also remove insulin from the blood.  They have increased importance in 
subcutaneous injection, due to the fact that the insulin bypasses first-pass 
metabolism [14].  
Although the exact mechanism is unknown, insulin is believed to be 
broken down within the cell using insulin degrading enzyme (IDE).  This enzyme 
performs site-specific cleavages as shown in Figure 2.3.  It is interesting to note 
that the majority of the cleavages occur closely spaced in a "cleft" in the molecule 
toward the back of this model and away from the receptor-binding region [14]. 
As discussed earlier, type 1 diabetes is caused by a lack of insulin 
secretion. This damage is often caused by disease or injury to the beta cells.   
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The lack of insulin results in a decrease of glucose utilization, which can lead to 
plasma glucose levels as high as 300-1200 mg/100 mL [15]. Type 2 diabetes is 
the term for patients who produce low levels of insulin, are insulin resistant or 
both.  These patients may opt for insulin treatment when other medications to 
improve insulin production and diet fail. Insulin is also a part of a number of 
anaerobic cascades, such as the reduction of sex hormone binding globulin.  Sex 
hormone binding globulin is a compound that binds to estradiol and testosterone 
rendering them inactive.  Because of this fact, insulin resistance can lead to 
polycystic ovary syndrome in women.  This is due to the fact that the extra insulin 
needed to control blood glucose levels also activates additional testosterone via 
its interaction with sex-hormone binding globulin [16].   
One known drawback to insulin therapy is that there is no commercially 
available insulin formulation that includes C-peptide. As described earlier, C-
peptide is also a derivative of proinsulin.  C-peptide is utilized in repair of the 
muscular layer of the arteries. It also has been shown to reduce the occurrence 
of cardiovascular problems, as well as neuropathy in diabetic patients.  One 
study showed that c-peptide may be capable of reversing neuropathy effects.  In 
addition, it has been shown to have significant positive effects on glomerular 
function [17].  
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2.1.2. Digestive Anatomy 
To be an effective oral delivery system, a drug must pass through the 
mouth, esophagus, and stomach, and arrive at the small intestine where it is to 
be absorbed.  This structure is demonstrated in Figure 2.4.  Unabsorbed material 
will pass through the large intestine and be expelled from the body.  The liver and 
pancreas also play an important role.  In the description that follows, emphasis 
will be placed on components that will affect protein absorption.  When the 
protein enters the stomach in the fasted state, it is exposed to pH conditions 
around 2.  Pepsinogen is secreted, which upon contact with hydrochloric acid 
(HCl) is activated to form pepsin.  Pepsin is active at a pH of 2.0-3.0 and inactive 
above a pH of 5.0 [15].  This enzyme provides about 10-20 % of total protein 
digestion. It accomplishes this via hydrolysis of the peptide linkages between 
amino acids [15]. 
The small intestine is an ideal site for absorption.  It is approximately 20 
feet long with a diameter of 1.5 inches and consists of 3 segments: the 
duodenum, jejunum, and ileum [18]. The proximities of these segments are 
shown in Figure 2.4. With regards to transport, it has been shown that the order 
of insulin transport across the various intestinal membranes was jejunum = ileum 
> duodenum > colon [19].  It has also been shown that insulin transport across 
the duodenum is significantly lower than that across the jejunum and ileum  [20]. 
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The small intestine consists of four layers of tissue: the serosa, muscularis 
externa, submucosa, and mucosa. The intestines are fed by the hepatic portal 
vein, which carries nutrients to the liver, where they are filtered prior to delivery to 
the body.  The inner layer of tissue is referred to as the mucosa (depicted in 
Figure 2.5), which is made up of 1-10 mm high circular folds that run 
circumferentially and project radially inward toward the lumen. These folds are 
covered with villi that are 0.5-1.5 mm high and occur at a density of 10-40 per 
square mm [18].  The villi are lined with absorptive enterocytes.  The blood 
vessels, which negotiate the center of the microvilli, supply the cells with oxygen 
and nutrients and also carry away nutrients absorbed from these cells.  The 
enterocytes themselves are coated in microvilli, which further increase the 
surface area. The combination of folds, villi, and microvilli increase the surface 
area of the intestines by a factor of 600 over a smooth cylinder of the same 
diameter [18].  Enterocytes also produce mucous, which allows molecules to 
stick to the surface of the cell.  Enterocytes are joined together by desmosomes, 
tight junctions, and gap junctions. Desmosomes serve as a mechanical link, while 
gap junctions serve as connecting channels that allow low molecular weight 
molecules to pass between cells. Tight junctions appear as a fusion of 
membranes which divide the cell into two distinct regions: the apical region which 
is in contact with the mucosa, and the basolateral region which is in contact with 
the serosal region [18].   
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Most protein digestion takes place in the small intestine.  In the small 
intestine, the insulin is exposed to trypsin, α-chymotrypsin, carboxypeptidase, 
lactase, and proclastase, all of which are produced by the pancreas.   If the 
protein reaches the brush boarder of the enterocytes, peptidases that protrude 
through the cell membrane to the exterior break the remaining polypeptides into 
tripeptides, dipeptides and amino acids. Amino acids, dipeptides, and tripeptides 
are actively transported across the enterocyte [15].  In the case of insulin, the 
trypsin, chymotrypsin, elastase and the enzymes of the brush border are the 
enzymes primarily responsible for degradation [21]. 
2.1.3. Cellular Transport Mechanisms 
As discussed previously, in order for insulin or any other protein or nutrient 
to be absorbed by the body, it must cross the enterocyte monolayer.  The various 
transport mechanisms are illustrated in Figure 2.6. There are two main classes of 
transport. The first is paracellular, which occurs between cells.  Paracellular 
transport is labeled with (1) in Figure 2.6.  The second type is transcellular, which 
occurs through the cells.  Transcellular transport (2a) can be further broken down 
into several different types.  The simplest method is diffusion, which represents 
the movement of solutes as a result of a concentration gradient. This method is 
only effective for very small molecules.  Carrier mediate transport (2b) occurs 
when a molecule binds with a carrier at one face and is released at the opposite 
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face of the membrane [18].  In endocytosis (2c), the cell membrane forms a 
container and engulfs a portion of the extracellular media. The engulfed material 
is pinched from the membrane and forms a vesicle.  If exocytosis occurs (2c), 
material in a vesicle migrates to the cell wall, combines with it, and then opens to 
the extracellular space where its contents are released [18].  One final possible 
form of transport is the efflux pathway. In this pathway, a molecule enters and 
departs the cell on the apical side of the cell. 
2.1.4 Cell Model of the Intestinal Epithelium  
Two cell types are commonly used to model the enterocytes of the 
intestinal epithelium. These cell types include Caco-2 cells, which are human 
colon adenoma carcinoma cells, and HT29-MTX cells, which are mucus-
secreting colon carcinoma cells.   The Caco-2 cell line is one of the most widely 
accepted epithelial intestinal cell models. This is because the cells form a well-
differentiated, polarized monomer with a brush border and tight junctions; visually 
appearing particularly similar to in vivo intestinal epithelium. Additionally, they 
produce typical enzymes, and are well characterized [22].  Unfortunately, these 
cells do not produce mucus, and because these cells are derived from the colon; 
they have tight junctions that are significantly tighter than those that exist in the 
small intestine.  These “tight” tight junctions make it more difficult for hydrophilic 
compounds to pass.  This feature is a hindrance because this model 
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underestimates paracellular permeability in vitro. Carrier mediated absorption is 
also lower in Caco-2 systems when compared to enterocytes in vivo.  Finally 
there is an over expression of P-glycoprotein; an intestinal efflux mediator [23]. 
HT29-MTX Cells are mucus-secreting colon carcinoma cells.  They form tight 
junctions, but they can be up to 30 times more permeable than Caco-2 cells [24].  
It is also known that these HT29 cells do not express p-glycoprotein.  HT29-MTX 
cells also form a polarized monolayer and develop an apical brush border. A co-
culture of these cells allows one to create a more physiologic model or determine 
which parameter has the greatest effect by altering cell ratios which subsequently 
alter mucus production, amount of p-glycoprotein, as well as the paracellular 
resistance [24].  
2.2. Rational for Alternative Drug Delivery Methods 
2.2.1. Side Effects From Subcutaneous Injection 
 When patients continually administer subcutaneous injections to the 
abdomen, often a fibrocollagenous scar results.  In 30% of cases, fat atrophy 
occurs around the injection site, giving the abdomen an unsightly, lumpy 
appearance [25].  If the patient switches to a pump injection system, they run the 
risk of contracting an infection (e.g. staph) at the injection site [25]. 
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2.2.2. Quality of Life Effects on Patient Compliance 
Both immediate and long-term effects of treatment often determine a 
patientsʼ quality of life.  Quality of life is affected by a number of reasons including 
side effects (such as hypoglycemia or fatigue), a decrease in disease-related 
symptoms, or a lifestyle change (such as injecting insulin or testing glucose 
levels).  The relationships between reasons affecting quality of life are shown in 
Figure 2.7.  These effects can in turn modify the patient's compliance and affect 
the risk of long-term complications of the disease. Finally, the decreased risk of 
long-term complications, such as retinopathy, nephropathy, stroke, or 
cardiovascular disease, increases not only the absolute number of years of life 
but also the amount of time during which the patient experiences better health 
and well-being [26].  It follows that a reduction in negative effects, such as side 
effects, and improvement in effectiveness and ease of use will improve patient 
compliance and subsequently quality of life. 
In addition to the high cost of treatment for diabetic patients, which 
averages $12,000 per person per year, insulin is currently only available in the 
US by injection or pump [27].  Both delivery methods do negatively affect the 
compliance of patients, due the fact that both methods have obvious side effects 
and represent a major change in lifestyle, requiring patients to continually monitor 
glucose injections.  Needle injection is probably the most intrusive as it is painful, 
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and due to the fact that a bolus of insulin is being released, local hypoglycemic 
effects can cause problems.  In addition, insulin solution should not be exposed 
to extreme heat; this can also present problems for the user, as many summer 
outdoor events may not be conducive to this condition [28].  Insulin delivered via 
pump has a significantly improved patient compliance, as it requires fewer steps 
for measuring glucose and delivering insulin.  However, many patients balk at the 
fact that the insulin pump should be removed during contact sports or sexual 
relationships, as this limits spontaneity [29].  As such, a more convenient form of 
insulin delivery is needed, the most desirable of which is oral drug delivery. 
2.3. Alternative Insulin Administration Routes 
2.3.1. Buccal Insulin Delivery 
 The soft pallet of the mouth is commonly called the buccal layer.  This 
area is absorptive and has low enzymatic stability.  In the buccal layer nutrients 
are carried away by the jugular blood vessel into the other parts of the body.  To 
enhance delivery, a number of surfactants have shown promise, including 
Pluronic® and lysalbinic acid that serve to improve the paracellular permeability 
[30, 31].  
There is one buccal insulin formulation that has been approved for use in 
Ecuador and India. This product, coined Oral-lyn®, utilizes insulin encapsulated 
in permeation enhancers delivered with a high-velocity inhaler. Oral-lyn® was 
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developed by Generex Biotechnology, a small startup company.  Due to 
promising results in these countries, Phase III clinical trials are underway in both 
the U.S. and Canada [32]. 
A disadvantage of this type of delivery system is that surfactants work by 
altering tight junctions or cell membrane conditions to allow paracellular 
transport.  If tight junctions are breached, this may also allow transport of 
pathogens or other undesirable molecules to enter the body. 
2.3.2 Pulmonary Insulin Delivery 
 The only non-invasive delivery method to make it to market in the United 
States is an inhalable formulation called Exhubera®.  Despite being hailed by the 
scientific community, the product was only on the market from September 2006 - 
October 2007 due to poor sales [33].  Pharmaceutical companies were convinced 
that the product would “sell itself” due to ease of use and the reduction in the use 
of needles.  Patients were discontent with the bulkiness of the inhalation 
apparatus and believed that increased benefit did not justify the cost [34].  A 
number of companies currently have alternative formulations undergoing 
research.  Theses companies are striving to make inhalable insulin less 
expensive as well as create smaller inhalers [35]. 
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2.4. Oral Insulin Delivery Developments 
As can be seen from the above discussion, the body is specifically 
designed to ensure that whole proteins do not cross the intestinal epithelium. 
This is a safety measure because proteins that enter the body may elicit an 
immune response. As a result, our goal is to allow insulin to cross the intestinal 
epithelium without altering the bodyʼs natural digestion and absorption processes 
for any other protein. 
2.4.1 pH Responsive Polymers  
A pH responsive hydrogel carrier has been developed in order to protect 
insulin from the harsh acidic environment in the stomach prior to releasing it into 
the small intestine. This system is comprised of poly(methacrylic acid-grafted-
ethylene glycol)  (P(MAA-g-EG)).  In the stomachʼs acidic environment, these 
gels are in a complexed state and thus have a small mesh size. This reduced 
mesh size results in limited diffusion of the drug inside the carrier. Once the 
particles pass into the small intestine, the pH increases and the complex 
dissociates, resulting in an increase in the mesh size of the gel.  This larger mesh 
size allows insulin to diffuse out of the gel.  A schematic of this process is shown 
in Figure 2.8.  These hydrogels were also seen to exhibit excellent 
mucoadhesion to the walls of the small intestine [36]. 
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A compound called Eudragit® is also known to protect compounds in the 
stomach and dissolves when it reaches the small intestine.  Eudragit® is 
currently used clinically for many different available drugs.  The bioavailability as 
it compares to injected insulin (100%) is 0.9%. P(MAA-g-EG) hydrogels have 
achieved a bioavailability as high as 16.2%.   
2.4.2. Polymer Decoration for Improved Mucoadhesion 
In earlier work, the PEG tethers in the P(MAA-g-EG) gels were 
functionalized with wheat germ agglutinin(WGA), a lectin that binds to 
carbohydrates in the intestinal mucosa. This binding led to both improved drug 
absorption and longer residence times, created by a 17% stronger mucoadhesion 
for the microparticles. Functionalization of P(MAA-g-EG) improved bioavailability 
to 11.9%  [37]. The improvement in drug absorption is considered to occur due to 
an opening of the tight junctions. Tight-junction strength was measured by 
transepithelial resistance of the membrane (TEER).  In cellular studies, P(MAA-g-
EG)-WGA particles decreased TEER by 30%  [37].  The primary critique of this 
work is that it is believed that opening the tight junctions long enough to allow 
proteins to pass may leave the small intestine epithelium susceptible to viral 
attack.  In addition, other whole proteins may also pass, which may lead to an 
immune response.  Carbohydrates are currently being studied in hopes of 
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gaining improved mucoadhesion, without causing significant disruption in the 
tight junctions of the intestinal epithelium.  
2.4.3. Poly(ethylene glycol) Modification Insulin 
  Poly(ethyele glycol) PEG is a linear or branched polymer with a 
highly flexible backbone. PEG is commercially available with a variety of different 
functional end groups.  PEG has a number of properties that make it excellent for 
pharmaceutical applications. It is soluble in both aqueous and organic solvents 
and has a well developed conjugation chemistry [8].  PEG is also nontoxic and 
has been approved by the FDA for use in foods and cosmetics  [37].  
Additionally, the FDA has approved two PEGylated proteins: PEG-adenosine 
deaminase, for the treatment of immune deficiency, and PEG-aspargainase, for 
the treatment of leukemia [38].  An incomplete list of PEGylated proteins that 
appear in the literature include asparganase, alkaline phosphatase, granulocyte 
colony stimulating factor, bovine liver catalase, ovalbumin, uricase, collagen, 
human growth hormone, trypsin, hemoglobin, interleukin-2, ribonuclease A, and 
of course insulin [8]. 
Probably one PEGʼs most significant properties is that it is extremely 
hydrophilic.  In aqueous solution, each ethylene oxide unit can bind up to three 
water molecules (see Figure 2.9).  It is also commonly believed that PEG can 
influence the structure of several molecular layers of water molecules when 
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suspended in an aqueous solution.  The combination of these properties is often 
referred to as a “hydration sphere”. The hydration sphere is one reason why PEG 
is so effective in repelling other polymers in an aqueous environment, causing it 
to be both nonimmunogenic and nonantigenic [8].  The attachment of PEG to a 
protein leads to the transfer of many of the polymerʼs properties to the resultant 
conjugate [8]. 
The modification of proteins with PEG creates a considerable increase in 
the circulating life of the protein in the bloodstream and also is known to reduce 
the proteinʼs immunogenicity and antigenicity. The increased circulating life is 
credited to masking of ligands as well as antigens recognized by cellular 
receptors via steric hindrance [39]. 
Conjugation of PEG to insulin will likely lead to three main 
pharmacological improvements. The first is a decrease in the clearance rate, thus 
leading to an increase in the time the protein is available. This is due to the fact 
that the size of the PEG molecule, plus the hydration sphere, is larger and thus is 
not cleared by the kidneys at the same rate [8].  The second improvement is a 
decrease in proteolytic degradation. This occurs because PEG sterically shields 
the molecule. Finally, it is more difficult for antigens to recognize the protein and 
thus receptor binding and subsequent clearance by the immune system is 
reduced [8]. 
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Many different activated PEGs are commercially available and are simple 
to use.  Methoxypoly(ethylene glycol)-succinimidyl propionate(mPEG-SPA)  [24] 
has been developed specifically for use with primary amines. PEG-SPA was 
conjugated to the B29Lys position insulin.  The reactive pH of PEG-SPA is from 
7-9, while the ideal pH for lysine conjugation is 10.  As a compromise, the 
reaction is performed at a pH at or around 9. 
Several significant studies have been previously performed on PEG-
insulin conjugates.  Tests on the physical stability on insulin were performed 
using an accelerated shake test. Samples were subject to horizontal shaking 
(100 strokes/minute) at 37°C and tested several times each day.  They were then 
analyzed for residual insulin concentration using RP-HPLC yielding the results 
shown in column 2 of Table 2.1.  Note that all insulin conjugates resulted in 
longer-term physical stability.  
 The bioactivities of PEG-insulin conjugates in the B29Lys and the B1Phe 
positions were also compared in a rat model.  As predicted, no difference 
between the sites of substitution existed because neither location is directly 
involved in receptor binding. A short PEG chain (750) was actually seen to 
improve the bioactivity.  However, increasing the length of the PEG was seen to 
decrease the bioactivity. This reduction is probably due to steric hindrance of the 
insulin-receptor interactions [8]. These results are also shown in Table 2.1. 
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 Another advantage of B29lys as the site for PEG conjugation, is the low 
level of humoral immunogenicity and antigenicity.  Humoral immunogenicity 
testing was performed on two types of mice C57 (high insulin responding) and 
A/J (low insulin responding). The preimmunization level of antibodies was taken 
as a baseline and subtracted from subsequent results. The mice were immunized 
with a dose of 5mg of sample/mouse/immunization, which was administered 
intraperitoneally. A second dose was given after 21 days.  Insulin specific 
antibodies IgG and IgE were measured 12 days after the second dose.  The 
highest level of insulin specific IgG and IgE antibodies were found in mice 
immunized solely with unmodified human insulin [8]. The group of mice 
immunized with pure insulin had between 14-315 times more insulin-specific Ig-G 
than any other group studied.  No insulin-specific immune response was 
observed with the PEG (2000) insulin conjugate at the B29Lys position [8].  
 In A/J mice, the experimental group immunized with only unmodified 
insulin subsequently produced from 8 to 64X more insulin-specific IgG 
antibodies.  Again, PEG (2000) insulin B29Lys had no appreciable immune 
response. 
 The antigenicity of PEG-insulin conjugates were detected using ELISA 
testing to quantify the amount of anti-IgG antibodies to quantify mice immunized 
with the various insulin conjugates.  All PEG-insulin conjugates had appreciably 
less relative antigenicity than regular insulin. Note that the PEG (2000) insulin 
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conjugate had no measurable antigenicity compared with zinc-insulin. It is 
believed that PEG-insulin conjugates help to mask antibody binding sites. As a 
result, an increase in molecular weight is believed to result in a more pronounced 
steric masking. 
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Figure 2.1.  Insulin and glucose metabolism in the cell.  First, insulin binds to the 
insulin receptor and activates the translocation of the GLUT-4 
transporter to the plasma membrane, which allows the entry of 
glucose molecules into the cell (1).  Once glucose enters the cells 
glycolysis and fatty acid synthesis occurs (2).  It is the fatty acids that 
signal the β cells to stop insulin production.  
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Figure 2.2. Schematic representation of the primary structure of human insulin. 
The possible amine reactive sites (A1Gly, B1Phe, B29Lys) available 
for conjugation are marked in red. 
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Figure 2.3. A schematic depicting the location of cleave sites on insulin when 
exposed to insulin degrading enzyme.  
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Figure 2.4. Schematic of the digestive tract.  Figure shows the location of the 
duodenum, jejunum and ileum. 
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Figure 2.5. Schematic of intestinal epithelium.   
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Figure 2.6. Methods of intestinal transport.  Schematic depicts various methods 
of transport across the intestinal epithelium, which include 
paracellular, (1) transcellular, (2a) carrier-mediated, (2b) 
endo/transcytosis, (2c) efflux pumps (3). 
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Figure 2.7. Factors that affect patient compliance. This model shows the 
relationship between compliance, treatment-related issues such as 
safety, efficacy, and convenience and measurable outcomes such as 
quality of life and years of healthy life.  This image was adapted from 
Tetsa and Simonson [26]. 
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Figure 2.8. This Figure depicts P(MAA-g-EG) anionic hydrogels.  At low pH, such 
as in the stomach environment, P(MAA-g-EG) hydrogels are 
collapsed due to hydrogen bonding.  This preventing the insulin from 
diffusing out of the polymer.  When hydrogels are exposed to a 
higher pH, such as in the environment of the small intestine, the 
hydrogen bonds break, the mesh size of the polymer increases, and 
the insulin can diffuse out of the polymer. 
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Figure 2.9. PEGylated insulin in water.  Each ethylene oxide group can bind with 
up to 3 water molecules.  This creates a “hydration sphere” assists in 
protecting the protein from proteolytic degradation. 
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Table 2.1.  Long term physical stability (T50%) and bioavailability. T50% was 
measured as the time elapsed to reduce insulin to 50% of the initial 
concentration under constant shaking.  The bioavailability was 
determined from subcutaneous injection in rats.  Table adopted from 
Kim et al. [9] 
 
 
 
T50%(days) Bioavailability 
Insulin 0.5 ± 0.3 --- 
B1Phe PEG (750) insulin 18.4 ± 2.8 104% 
B1Phe PEG (2000) insulin 20.7 ± 4.1 83% 
B29Lys PEG (750) insulin 4.3 ± 1.1 112% 
B29Lys PEG (2000) insulin 8.6 ± 1.7 85% 
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CHAPTER 3 
OBJECTIVES 
 
For an oral drug delivery system to be successful, one must protect insulin 
from acid hydrolysis in the stomach and proteolytic degradation in the small 
intestine.  The bioavailability must also be improved by improving transport, 
solubility and by localizing the drug at the absorption site.  Any modifications 
made to the drug or carrier must not diminish the bioactivity or stability. 
One solution that has shown promise for improving the bioavailability of 
orally delivered insulin, is the use of anionic pH sensitive P(MAA-g-EG) hydrogels 
as a drug carrier. P(MAA-g-EG) hydrogels remain collapsed in the stomach and 
expand when they reach the small intestine; effectively protecting the protein 
from acid hydrolysis in the stomach and allowing it to be released in the small 
intestine.  Bioavailabilities have been measured as high 12.8%.  The main 
drawback for this solution is that once the insulin is released from the polymer, it 
is exposed to enzymes that begin to break it down. 
The objective of this project was to overcome these obstacles by the covalent 
attachment of Poly(ethylene glycol) (PEG) to insulin.  PEG is advantageous 
because it has been shown to lead to better stability, resistance to fibrillation, 
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equivalent bioactivity, decreased immunogenicity, longer residence times, and 
improved mucoadhesion in related applications.  
 
The specific aims are as follows: 
(1) Develop and characterize a high yield, site-specific reaction for PEGylated 
insulin with limited steps and simple purification. 
(2) Determine the cytotoxicity using fibroblasts and the transport properties of 
PEGylated insulin using a novel intestinal epithelium model. 
(3) Determine the bioavailability and in vitro intestinal transport properties of 
PEGylated insulin using a rat model. 
(4) Develop a P(MAA-g-EG) hydrogel carrier for use with PEGylated insulin. 
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CHAPTER 4 
SYNTHESIS AND CHARACTERIZATION OF PEGYLATED INSULIN 
 
4.1 Introduction 
 For the past few decades, a great deal of work has focused on attempts to 
develop noninvasive methods of insulin delivery with the oral route clearly being 
the most convenient and desired.  However, the oral route will encounter a 
number of barriers such as the presence of proteolytic enzymes in the 
gastrointestinal tract, harsh acidic environment in the stomach, chemical 
instability, low solubility and poor permeability of proteins across biological 
membranes.  Therefore, instead of the development and use of a new individual 
technology, the convergence of a number of different technologies is needed in 
order to address all barriers.  
 One way to avoid proteolytic degradation and chemical instability, as well 
as improve solubility is to conjugate poly(ethylene glycol) (PEG) to the insulin 
molecule.  PEG is a flexible, hydrophilic polymer; in an aqueous solution, 2-3 
water molecules per ethylene oxide unit will coordinate around the polymer. This 
effectively creates a hydration sphere that can protect the PEG and molecules 
associated with it  [1, 2].   Furthermore, this hydration sphere acts to prevent the 
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adhesion of other polymers, which leads to a reduction in fibrillation, antigenicity, 
proteolytic degradation, and clearance rate from the body (which can decrease 
the dosage frequency)  [3, 4]. Additionally, PEG has been shown to be 
biocompatible as it has been approved for use in a variety of pharmaceutical, 
cosmetic, and food products  [4, 5]. 
The insulin molecule has 3 active sites that can be used for 
functionalization; A1-Glycine (A1Gly), B1-Phenylalanine (B1Phe), and B29-
Lysine (LysB29).  The location of these sites is shown in Figure 2.4. Previously 
published formulations reacted in a non-specific manner with these sites using 
succinic propionic anhydride activated PEG (SPA-PEG) [6]. Typically, a selective 
protection is performed in order to ensure the PEGylation occurred in a particular 
location on the insulin molecule.   For example, if B29Lys is the targeted reaction 
site, dimethylmalic anhydride (DMMA) can be used to react with insulin to protect 
A1Gly and B1Phe, Figure 4.1.  If the B1Phe was the targeted location for 
conjugation, the A1Gly and B29Lys can be blocked with di-tert-butyl bicarbonate 
(t-boc).  In both instances, once the reaction was complete, the protein solution 
was dialyzed to remove the unreacted blocking reagent.  Once fully protected, 
the protein underwent nucleophilic addition to the carbonyl of SPA-PEG (Figure 
4.2) and finally was purified with reverse-phase HPLC.  This method was time-
consuming, led to a mixture of products, and a low yield [7].  Thus, it was 
necessary to develop new conjugation chemistry to resolve these issues.  
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As a result, a PEG-nitrophenyl carbonate conjugation scheme was studied 
to determine if fewer products or higher yield would result.  The same three 
amines are possible reaction sites:  GlyA1, PheB1, and LysB29  [4]. The reaction 
scheme and possible reaction sites are shown in Figure 4.3.   Polymers with 
molecular weights less than 5000 were chosen for the study, as it has been 
previously demonstrated that longer chain lengths limit bioactivity  [4].  
4.2 Materials and Methods 
4.2.1 Dimethylmalic Anhydride Blocking of Insulin Molecule  
To ensure that the PEGylation reaction was site specific at the B29Lys 
position, insulin was blocked with dimethylmalic anhydride (DMMA). This served 
to protect N-terminal amines, which may potentially react with an activated PEG.  
A 25 mg sample of bovine insulin (Sigma-Aldrich, St. Louis, MO) was added to 
1.5 mL of 1 N HCl and 3 mL of pH 6.9 phosphate buffered saline (PBS).  Once 
the insulin was dissolved in solution, the pH was adjusted to 6.9 with 1N NaOH.  
Dissolved insulin was then reacted with 3.5 mg of DMMA under constant stirring 
for 0.5 hours. As the DMMA reacts with the solution, the pH begins to decrease.  
The pH of the solution is maintained between 6.8-6.9 with 1M Na2CO3.  This 
reaction was repeated two additional times, the result being that 10.5 mg of 
DMMA was added to the solution at a controlled pH of 6.8-6.9.  Finally the 
reaction mixture was dialyzed (Float-a-lyzer, MWCO 3500; Spectrum 
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Laboratories, Rancho Dominguez, CA) in PBS at a pH of 6.9 for at least 24 hours 
for the purposes of removing unreacted DMMA.  This reaction is shown in Figure 
4.2. 
4.2.2. Conjugating PEG to the Lysine B29 Bocation on Insulin 
Once the insulin had been blocked and dialyzed, it was ready for PEG 
conjugation.  The pH of the dissolved insulin from the previous step was 
increased to a pH of 9 with 1M Na2CO3.  SPA-PEG with a molecular weight of 
5000 (Nektar Therapeutics, San Carlos, CA) was added at 2:1 molar rato of 
PEG-SPA:insulin.  The solution was allowed to react for 2 hours at room 
temperature and again dialyzed against PBS to remove unreacted PEG.  The 
reaction scheme for PEG-SPA is shown in Figure 4.1. 
4.2.3 Preparative HPLC for Purification of PEGylated Insulin 
Synthesized PEG-insulin was further purified using a preparative high 
performance liquid chromatography column (HPLC). The HPLC was 
manufactured by Amersham Pharmacia Biotech (now GE Healthcare, 
Piscataway, NJ) with a SourceTM SRPC St 4.6/150(Amersham Biosciences, 
Piscataway, NJ) column. A typical two solvent setup was used, H20 with 1% 
trifluoroacetic acid (TFA) (Solvent A) and acetonitrile with 0.8% TFA (solvent B). 
The column was equilibrated with 2 column volumes Solvent A with a flow rate of 
2 mL/minute.  The unpurified sample was then injected into the HPLC.  The 
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solvent ratio started at 43% Solvent B, and increased linearly by 4.93% per 
column volume.  The conjugate was detected at 215 nm and 2 mL fractions with 
were collected with preweighed glass test tubes as the product eluted from the 
column.  Finally, the product was dried with a centrifuge vacuum drier 
(Vacufuge® Eppendorf Vacuum Concentrator Model 5301, Hamburg, Germany). 
4.2.4 Mass Spectrometry 
Matrix solution was made by placing 20 mg/mL α-cyano-4-
hydroxycinnamic acid (Fisher Sciences Hampton, NH) in aqueous solution with 
2% formic acid and heating to solublize.  A 0.5 μL sample of matrix solution was 
spotted on a steel sample plate.   A 0.5 μL sample of protein, obtained directly 
from the collected HPLC fractions, was spotted three times and allowed to dry.  If 
the spot appeared amorphous, 0.5 μL of 0.2% formic acid was added to the spot 
and allowed to dry.  The sample was then analyzed in a matrix-assisted laser 
desorption/ionization-time of flight (MALDI-TOF) mass spectrometer system 
manufactured by PerSeptive Biosystems under vacuum with a laser intensity of 
500. All fractions in which PEGylated insulin were detected were dried with a 
centrifuge dryer (Vacufuge® Eppendorf Vacuum Concentrator Model 5301, 
Hamburg, Germany) and stored at -15°C.   
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4.2.5 Synthesis and Purification of PEGylated Insulin Using Nitrophenyl 
Carbonate-PEG 
Bovine insulin (Sigma St. Louis MO) was added to pH 8 PBS buffer with 
ethylenediaminetetraacetic acid (EDTA) at a ratio of 5 mg/mL and was dissolved 
in solution by incubating for 10 minutes at 37°C.  Once dissolved, a 2:1 molar 
ratio of PEG-nitrophenyl carbonate (NPC):insulin with a molecular weight of 
1000, 2000, or 5000 g/mol was added slowly to the mixture (Laysan Bio Arab, 
Alabama). The mixture was then reacted for 18 hours at 37°C under gentle 
agitation.  Upon completion of the reaction, up to 6 mL of the conjugate solution 
was purified with a Vivaspin® 20 centrifuge concentrator with a molecular weight 
cutoff of 5000 g/mol (Sartoriums Stedim Biotech Abagne, France).  The reaction 
mixture was placed in the concentrator and centrifuged at 1700 m/s2 for a period 
of one hour at 4°C.  At this time, the solution collected beneath the filter was 
removed and PBS was added to the upper chamber and aspirated in order to 
resuspend the insulin conjugate.  The mixture was then centrifuged for an 
additional hour to further remove any unreacted components.  Once purified, the 
resulting mixture was analyzed with mass spectrometry as discussed earlier, 
dried with a centrifuge vacuum drier, and stored at -15°C until use.  
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4.2.6. High Definition Liquid Chromatography (HPLC) 
The purity of the NPC-PEG conjugate was determined using a Waters 
2695 Separations HPLC with a Symmetry 300TM C4 column.  A sample of 20 µL 
was injected into the column, which ran a mixture of 70% water with 0.1% TFA 
and 30% acetonitrile with 0.8% TFA at a flow rate of 1 mL/min. The sample was 
detected at 220 nm.  Once conjugation was confirmed with mass spectrometry, 
the solution was dried with a centrifuge vacuum dryer. 
4.2.7 Conjugation Location 
In order to determine the location of conjugation, the conjugate was 
purified to 99.9% purity with preparative HPLC and then dissolved in tris base at 
pH 8. Next, the PEG (2000)-insulin (2KPI) was selectively broken into identifiable 
peptides.  To reduce the disulfide bonds, purified PEGylated insulin was 
subsequently exposed to diothiothreitol (DTT) (Fisher Sciences Hampton, NH) at 
a 2:1 molar ratio of DTT: number of sulfides on PEGylated insulin in PBS pH 7.4 
for two hours at 37°C. 2-nitro-5-thiocyanobenzoate (NTCB), which was 
purchased from Sigma-Aldrich (St Louis, MO), was then used to break cysteinyl 
residues at the N-terminal side of the amine [15].  A 10-fold molar excess of 
NTCB was added over the approximate number of cysteines and incubated at 
37°C for 30 minutes in order to modify the residue.  This reaction is shown in 
Figure 4.4.  The pH was then raised to 9.0 with sodium hydroxide and the 
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solution was reacted for 16 hours in order to cleave the modified peptide.  The 
peptides fragments were separated using preparative HPLC and analyzed for 
molecular weight with MALDI-TOF MS.  The weights of the peptide fragments 
were calculated with and without possible conjugation.  The presence or absence 
of PEG was determined by examining the resulting spectra for polydispersity.   
4.3 Results and Discussion 
4.3.1 Analysis of PEGylated Insulin Created Using SPA-PEG 
Previously studied insulin conjugations typically involved a multi-step 
process. Amine groups on insulin that were not intended to participate in the 
conjugation were often protected through the use of DMMA, which blocks A1Gly 
and B1Phe, or t-boc which blocks A1Gly and B29Lys under carefully controlled 
pH conditions in order to improve the homogeneity of the conjugate [8, 9].  
Separation of blocked and unblocked insulin was difficult due to small differences 
in molecular weight, leading to inhomogeneties even within insulin that has been 
protected. Insulin was also typically protected to prevent conjugation reactions at 
the A1Gly position, which lowers the bioactivity of the molecule  [10].  Once the 
protection was complete, the insulin was typically PEGylated using PEG-succinic 
propionic anhydride, a reaction that had a low yield (due to the competing 
reaction with water), was not site specific, and was difficult to purify; ultimately 
leading to overall poor yields.   
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As the reaction was not site specific, protection of possible reaction 
functionalities was often carried out prior to conjugation.  A spectra of this sample 
created using reverse-phase HPLC is shown in Figure 4.5.  The spectra revealed 
4 peaks; three narrow peaks(I) and a single broad peak [11]. It is believed that 
the three narrow peaks represent pure insulin and insulin with 1 and 2 DMMA 
protecting groups. The broad peak represents PEG-insulin, which was collected  
[11].  The purity of the PEG-insulin conjugate was analyzed using matrix-assisted 
laser desorption ionization time-of-flight (MALDI-TOF).  MALDI-TOF estimates 
molecular weight, which also indicates the number of PEG chains on the 
molecule.  The molecular weight of insulin is estimated to be 5733 and the 
number average molecular weight of the PEG-SPA (5000) is 5382.  The final 
molecular weight is estimated to be 11,116. A MALDI-TOF MS from Perseptive 
Biosystems (Foster City, CA) was used for this analysis. Fractions were 
evaluated by placing 10 mL of matrix on the sample plate with a micropipette. 
The matrix was comprised of α-cyano-4-hydroxycinnamic acid.  This molecule 
was chosen because of its strong absorbance in the UV range and its low 
molecular weight, allowing it to easily vaporize. Approximately 10 µL of sample 
from the PEGylated insulin fractions were placed over the matrix solution. The 
sample was allowed to dry and then analyzed using a laser intensity greater than 
300 nm.  If the molecule were not successfully protected, insulin may be 
PEGylated more then once, as shown in Figure 4.6. In comparison, Figure 4.7 
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shows the mass spectra of unconjugated insulin; note the sharpness of this peak 
as this is typical of monodisperse samples, akin to a large number of body 
proteins.   
Finally the PEGylated insulin was purified with preparative HPLC and 
fractions were combined and subsequently dried with a centrifuge vacuum 
concentrator. While the final total estimated yield was approximately 46.5 mg if 
the conjugation occurred at a 1:1 ratio, experimentally after purification the dry 
weight of the conjugate ranged between 2-4 mg, a 4.3-8.6% yield. 
4.3.2. Analysis of PEGylated Insulin Using NPC-PEG 
An alternate reaction scheme was developed in an attempt to eliminate 
the protection step, and increase the reaction yield, simplifying the reaction and 
eliminating waste. Insulin was conjugated to PEG using a nitrophenyl carbonate 
activated PEG.  A number of PEG molecular weights were used; 1000, 2000 and 
5000 g/mol.  These values were chosen as previous results suggested that larger 
PEG chains limited bioactivity [4].  The reaction was carried out for 18 hours. As 
such, the reaction was slower than the previously studied SPA-PEG (4 hours), 
but yielded insulin that was 66.86% PEGylated (2KPI).  
The byproduct of this reaction is p-nitrophenol, which is a phenolic 
compound that has a nitro group opposite a hydroxy group on the benzene ring.  
It exists in two different polymorphs when crystalline.  The  α-form is clear and is 
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unstable at room temperature.  The β-form is yellow, stable at room temperature 
and gradually turns red upon exposure to light.  P-nitrophenol usually exists as a 
mixture of these two forms.  This compound has been shown to irritate the eyes, 
skin and respiratory tract and cause vomiting when ingested.  Fortunately, the 
molecular weight is only 139 g/mol; making it easy to separate from larger protein 
reactants, such as PEG and insulin with a size exclusion method, such as 
dialysis. P-nitrophenol was used to produce amide moieties in peptide synthesis, 
medications and fungicides.  The reactants were purified using centrifuge 
purification and characterized using analytical HPLC and MALDI-TOF MS.   
Purification was carried out using a Vivispin® 5000 molecular weight cutoff 
(mwco) filter. Centrifugation with this filter was continued until the yellow solution 
became colorless, indicating that much of the p-nitrophenol had been removed 
from the solution. As verified by the analytical HPLC results in Figure 4.8 for 
2KPI, much of the unreacted insulin was removed from the product. Insulin was 
represented by the peak centered around 4.75 minutes.  The broad peak 
centered around 7 minutes represents PEGylated insulin.  This conjugate eluted 
over a longer period of time and is more irregular than is typical of proteins, due 
to the polydispersity of the PEG.  The trace indicates that centrifuge purification 
improved the percentage of PEGylation to 84.07%. 
The molecular weight and polydispersity was investigated with MALDI-
TOF MS.  To perform this analysis, the laser beam serves as the desorption and 
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ionization source. The matrix plays a crucial role in this technique by absorbing 
the laser light and causing the target to vaporize. In order to analyze any sample, 
it is necessary to ensure that the sample is crystallized prior to analysis.  In the 
case of PEGylated insulin, if it is simply spotted on and dried, PEGylated insulin 
typically appears amorphous.  When this occurs, the compound is typically 
undetectable.  Recrystalizing with 0.2% formic acid improves its detectability.  
Figure 4.9 and 4.10 shows the mass spectrometry results from the 
analysis of successfully and unsuccessfully conjugated 2KPI respectively. For 
2KPI, a single polydisperse peak exists at a molecular weight around 8000 g/mol.  
This confirms that not only did PEGylation occur, it occurred at a ratio of 1 
molecule insulin (5733) to 1 molecule PEG (2000). This is significant, as this 
occurred when a significant molar excess of PEG was used for all 3 molecular 
weights studied. Figure 4.11 and 4.12 depict similar mass spectrometry results 
from successfully conjugated 1KPI and 5KPI. 
As depicted in Figure 4.6, it was believed that NPC-PEG could react at as 
many as 3 places on the insulin molecule. However, NPC-PEG has a much lower 
reactivity than SPA-PEG. It is believed that the specificity of the NPC-PEG 
reaction was enhanced over the SPA-PEG reaction because of the reduced 
reaction time for NPC-PEG. This belief is based on the reactivity-selectivity 
principle, which states that the more reactive the chemical compound, the less 
selective the reaction; in this way allowing selectivity to be obtained under the 
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right conditions [12]. Once conjugation was confirmed, the sample was dried with 
a centrifuge vacuum dryer.  When 100 mg of insulin was reacted with NPC-PEG 
with a molecular weight of 2000, the dry weight was approximately 120 mg; 
89.5% of the expected value.  
The site of conjugation was verified by predicting the molecular weights of 
each fragment, separating each fragment, and analyzing the molecular weight 
with MALDI-TOF MS.  All but one fragment displayed minimal polydispersity, 
while the polydispersity of the fragment containing PEG was visible.  The 
molecular weight range of the fragment was measured to be 2906-3439. This 
value corresponds to the B29Lys protein fragment, which has an estimated 
weight average molecular weight of 3307; and an estimated number average 
molecular weight of 3208.  This is significant, because this reaction allows for 
high-yield site specific PEGylation of insulin.  The conjugation location is also of 
importance, as the B29Lys position was not shown to affect the activity of the 
insulin. 
4.4. Conclusions 
PEGylated Insulin conjugates were created using two different types of 
activated PEG molecules, SPA-PEG and NPC-PEG.  NPC-PEG represented a 
major improvement in insulin PEGylation, with a higher reaction yield and major 
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simplification in the purification process.  In addition, the conjugation occurred at 
a 1:1 ratio, making experiments that utilize PEGylated insulins more consistent  
due to improvements in homogeneity. 
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Figure 4.1. DMMA blocking of the N-Terminal amine groups. At pH 6.8-6.9, the 
N-terminal amine groups (pKa 7.5-8) are partially deprotonated and 
are able to react with DMMA, while the B29lys (pKa 10.5) remains 
protonated; effectively blocking reaction with DMMA.  This reaction 
occurs through a nucleophilic attack of the nitrogen on the carbonyl 
on the 5-membered ring of DMMA. Reaction adapted from thesis of 
Kavimandan. 
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Figure 4.2. The reaction scheme for PEG-SPA and protein.  For this reaction to 
occur, the nitrogen on the terminal amines or B29Lys (in the case of 
insulin) undergoes a nucleophilic attack on the carbonyl of the 
activated PEG.   
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Figure 4.3. Expected possible reaction sites (A1Gly, B1Phe, and B29Lys) for 
nitrophenyl carbonate PEG on the insulin molecule. For this reaction 
to occur, the nitrogen on one of the depicted amino acids executes a 
nucleophilic attack on the carbonyl group on the NPC-PEG molecule. 
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Figure 4.4. The α and β chains of insulin modified with NTCB in PBS.  After 
raising the pH to 9, the protein is cleaved at the N-terminal side of 
the cysteine residues.  
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Figure 4.5. Reverse-phase HPLC spectra from SPA-PEGylation reaction.  Note 
that the first 3 peaks represent insulin and insulin blocked with DMAA 
(I). The large peak represents PEGylated insulin.  
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Figure 4.6. Insulin PEGylated with SPA-PEG (5000) without DMMA blocking.  
PEGylated insulin with 1 PEG chain had a molecular weight around 
11,000, while PEGylated insulin with 2 PEG chains had a molecular 
weight around 16,000. 
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Figure 4.7. MALDI-TOF MS results from unconjugated insulin.  Note the narrow 
polydispersity of the insulin peak, typical of many proteins.  
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Figure 4.8. Reverse Phase-HPLC analysis of 2KPI before and after using 
Vivaspin at 220 nm. The blue trace represents the spectrum prior to 
purification with Vivaspin (66.86% PEGylated).  The black trace 
represents the spectrum post purification (84.07% PEGylated). 
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Figure 4.9. MALDI-TOF MS spectrum of PEG (2000) insulin.  
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Figure 4.10. MALDI-TOF MS of an unsuccessful PEGylation reaction. The broad 
around 2000 g/mol represents unreacted PEG.  Unreacted insulin is 
also detectable in this spectra. 
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Figure 4.11. MALDI-TOF MS spectrum of PEG (1000) insulin.  
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Figure 4.12. MALDI-TOF MS spectrum of PEG (5000) insulin.  
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CHAPTER 5  
CELLULAR CHARACTERIZATION OF TRANSEPITHELIAL RESISTANCE, 
PERMEABILITY AND CYTOCOMPATABILITY OF PEGYLATED INSULIN 
 
5.1. Introduction 
Although the intestinal epithelium is multi-layered, the innermost layer is 
the most important for determining absorption.  The mucosa is comprised of 
fingerlike villi that are 0.5-1 mm long.  Individual cells are cillilated to further 
increase surface area, and therefore provide more area for absorption.  Each 
villus contains a loose connective tissue core called the lamina propria core, a 
capillary vessel network, and a lymphatic capillary called a lacteal.  Nutrients 
absorbed by the epithelial cells enter the capillaries where they are carried to the 
portal vein and filtered by the liver.  Some nutrients are also absorbed by the 
lymphatic capillary system in order to allow the body to express proper immune 
defenses [1]. 
The epithelium is comprised of a number of columnar epithelial cell types; 
enterocytes, goblet cells, endocrine cells and Paneth cells.  Goblet cells are 
ciliated absorptive cells that produce mucus. Endocrine cells secrete digestive 
juices and hormones.  Panethʼs cells serve a lymphatic function as they secrete 
α-defensins, hydrophobic peptides and positively charged domains that have the 
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ability to interact with phospholipids in the cell membrane.  These cells are 
triggered to secrete defensins when exposed to gram negative or gram positive 
bacteria as well as a number of bacterial secretions.  They also secrete lysozyme 
and phospholipidase A, and also have the ability to perform phagocytosis. The 
primary purpose of Panthʼs cells is to protect the adult stem cells that differentiate 
into the intestinal epithelial cells [2]. 
 Cultured epithelial cells have been successfully used as tools for the 
screening of drug permeation and transport during the last two decades [3] as 
these studies have been shown to be reproducible and correlate to in vivo data 
[4].  One particularly physiologically relevant cell type is Caco-2, an immortal 
human adenocarcinoma cell line.  This cell line is advantageous as it displays 
many of the characteristics of the human epithelial layer; including the production 
of a number of physiologically relevant enzymes, a brush border, the formation of 
tight junctions and carrier mediated transport systems for vitamin B12, D-glucose, 
amino acids, and dipeptides [5]. Cells reach complete differentiation around 3 
weeks. One drawback to Caco-2 cells is that this model does not have a mucus 
layer and the tight junctions are not as permeable as those found in the small 
intestine.  In addition, the intestinal epithelium consists of a variety of different cell 
phenotypes, with goblet cells and enterocytes being the most common cell type 
[5]. 
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 It follows that co-cultures of goblet cells and enterocytes would lead to a 
more physiological model.  HT29-MTX, is a goblet clone cell variant of HT29 cells 
derived from human colorectal cancer that was adapted to 10-6 M methotrexate, 
which served to cause them to differentiate into cells representative of the small 
intestine [6]. These cells have microvilli, microfilaments, large vacuolated 
mitochondria, smooth and rough endoplasmic reticulum with free ribosomes, and 
a reduced amount of lysosomes.  This cell line produces mucus, the secretory 
components of IgA, carcinoembryonic antigen, transforming growth factor beta 
binding protein, and is highly permeable [7].  HT29 –MTX cells produce a dense 
mucus gel with numerous mucus buds on their apical surface. However, this gel 
is labile and can be removed by extensive washing [5].   
 Transport is classified by two major categories, transcellular and 
paracellular.  Transcellular transport has a number of different possible 
mechanisms, as depicted in Figure 2.8.  Transcellular transport occurs between 
the cells, and paracellular transport occurs within the cells. There are a number 
of types of paracellular transport, which include carrier mediated transport, 
endocytosis and exocytosis and efflux pumps.  Efflux pumps take nutrients that 
have diffused into the epithelium and eject them back out into the lumen of the 
small intestine [8]. 
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 Previous research optimized co-culture ratios based on transepithelial 
resistance, cell markers and permeabilities. Conveniently, it was determined that 
a 1:1 ratio of HT29-MTX cells to Caco-2 cells optimized these characteristics. As 
it is believed that peptides likely cross the epithelium paracellularly, 
transepithelial resistance (TEER), which is a measure of the “tightness” of tight-
junctions was optimized to be as close to human physiologic values as possible 
[7].  TEER values for Caco-2 monolayers range between 1400 and 2400 Ωcm2 
while TEER values range from 20 Ωcm2 in the jejunium to 100 Ωcm2 in the large 
intestine.  A 50:50 co culture was able to reduce the TEER to 482 Ωcm2, which is 
much more physiologically relevant [7].  
 NIH 3T3 murine fibroblasts are often used as cytocompatability models as 
they are well characterized and are abundant in the body; present in large 
quantities in the extracellular matrix of many body organs as they manufacture 
glycosaminoglycans, collagens, reticular and elastic fibers, as well as 
glycoproteins. 
 In this study, we synthesized and purified PEG-insulin conjugate created 
using (nitrophenyl carbonate-PEG) NPC-PEG. We evaluated the effects of 
PEGylation on transepithelial resistance and apparent permeability with Caco-
2/HT29-MTX epithelial cells.  In addition, we determined the cytocompatability of 
this conjugate using 3T3 murine fibroblasts. 
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5.2. Methods and Materials 
5.2.1. Culture of Intestinal Epithelial Cells 
Caco-2 cells were purchased from ATCC (Rockwell, MD), while HT29-
MTX cells were generously donated by professor Thecla Lesffleur (Robert Debre 
Hospital, Paris, France).  Cells were stored under liquid nitrogen in 95% 
Dulbeccoʼs Modified Eagles Medium (DMEM) (Mediatech, Manassas VA) and 
5% DMSO until use.  When unfrozen, cells were cultured in DMEM with 4.5 g/L 
sodium pyruvate and L-glutamine (Mediatech, Manassas VA), 20% fetal bovine 
serum (FBS) (Fisher Scientific, Hampton NH), 1% Non-essential amino acids 
(Irving Scientific, Irving CA), and 1% Penicillin/Streptomycin/Amphotericin-B 
(Pen/Strep/Amp-B) (Mediatech Manassas, VA) during the first passage.  All 
contents were sterile filtered with a 0.2 μm filter into a 500 mL media flask.  
Media was aliquotted into sterile 50 mL test tubes and refrigerated until use. Both 
cell types were cultured and sustained on 75 cm2 polycarbonate flasks (Corning 
Lowell, MA) at 37°C and 5% CO2.  Epithelial cells were fed every 2-3 days with 
10 mL of pre-warmed media and passaged when they reached 80% confluence.  
This typically occurred on day 5 or 6.  During the second passage and all 
following passages, FBS was reduced to 10% of the total medium [5, 7]. 
Passaging was performed by first washing cells twice with 5 mL of Hankʼs 
Balanced Salt Solution (HBSS) without Ca++ or Mg++.  Cells were then incubated 
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with 0.5-1 mL of 0.5% trypsin/0.2% ethylenediaminetetraacetic acid (EDTA) for 5 
minutes. In order to stop the reaction, 4 mL of complete media with 10% FBS 
was added to stop the reaction.  The cells were then aspirated 20 times within 
the flask to reduce cell clumping and then transferred to a sterile 50 mL flask.  
Cells were then counted with a hemocytometer (Fisher Scientific, St Louis MO) 
and reseeded in a sterile environment.  Both types of cell are typically reseeded 
at a density of 2.5 x105 cells/cm.  HT29-MTX cells were used for experimentation 
at passage 8-20, while Caco-2 cells were used for experimentation between 
passage 60-80. 
5.2.2. Transport of PEGylated Insulin 
Cellular transport was investigated in the presence of microparticles.  A 
50:50 co-culture of Caco-2 and HT29-MTX cells was cultured on a 0.2 μm pore 
size polycarbonate 12-well Transwell® culture plate in media for 21 days.  The 
media comprised of DMEM with 4.5 g/L sodium pyruvate and L-glutamine, 20% 
FBS, 1% non-essential amino acids, and 1% Pen/Strep/Amp-B during the first 
passage. 
The medium was removed from the apical and basolateral chambers and 
replaced with HBSS containing 1.26 mM Ca2+.  Cells were allowed to equilibrate 
for 1 hour.  The HBSS was replaced with a solution containing 0.2 mg/mL bovine 
insulin, 0.5 mg/mL BSA and 1 mg/mL P(MAA-g-EG) microparticles crushed to > 
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43 µm in HBSS.  BSA is used to limit non-specific adhesion.  Samples were 
collected in the apical chamber at the initiation and termination of the experiment; 
0 and 3 hours respectively.  Basolateral samples were taken at 0, 30, 60, 120 
and 180 minutes.  Volumes were subsequently replaced with pre-warmed 
solutions containing 0.5 mg/mL BSA in HBSS.  Finally, insulin concentration was 
measured using a bovine insulin sandwich ELISA (Mercodia Uppsala, Sweden). 
Papp was calculated by the following equation:  
   (5.1) 
Here, J represents the flux and is calculated by determining the slope of the 
linear plot of drug transport versus time, A is the surface of the cell monolayer 
and Co is the initial concentration in the apical chamber. 
5.2.3. Transepithelial Resistance(TEER) of Cells Exposed to PEGylated 
Insulin 
TEER was used to evaluate the tight junctions of epithelial cells.  A 50:50 
co-culture of Caco-2 to HT29-MTX cells was cultured on a 0.2 μm pore-size 
polycarbonate 12-well Transwell® in media for 21-24 days or until TEER values 
stabilized. The media comprised of DMEM with 4.5 g/L sodium pyruvate and L-
glutamine, 20% FBS, 1% non-essential amino acids, and 1% Pen/Strep/Amp-B 
during the first passage.  TEER measures the resistance across the cell 
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monolayer from apical to basolateral using a chopstick electrode as shown in 
Figure 5.1. During culture, measurements were taken every other day before 
changing the media.  While the sample was being measured, the Transwells® 
were placed on a temperature-controlled warming plate at 37°C as resistance is 
a function of temperature. 
In order to obtain the resistance across the cell monolayer, it is important 
to subtract the resistance due to the media and the polycarbonate substrate.  As 
such, one blank existed on each plate, and this measurement (Rblank) was 
subtracted from the measured value (Rmeasured) across the cellular membrane to 
yield the true value (Rtrue) as shown in the equation that follows: 
Rtrue = Rmeasured - Rblank  (5.2) 
Resistance values were multiplied by the area, to give unit area resistance in 
Ωcm2.    
At the start of the experiment, the medium was removed from the apical 
and basolateral chambers and replaced with HBSS containing 1.26 mM Ca2+.  
Cells were allowed to equilibrate for 1 hour.  The HBSS was replaced with a 
solution containing 0.2 mg/mL bovine insulin or PEGylated bovine insulin and 0.5 
mg/mL bovine serum albumin (BSA) and 1 mg/mL p(MAA-g-EG) microparticles 
crushed to > 43 µm in HBSS.  BSA was used to limit non-specific adhesion.  
TEER measurements were taken just after the HBSS was replaced with solution 
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containing insulin samples, microparticles and BSA (t0) and after 30, 60, 120 and 
180 minutes. 
5.2.4. Cytotoxicity of PEGylated Insulin 
Murine 3T3 fibroblasts (ATCC, Rockwell MD) were seeded at 9000 cells 
per well on 96-well plates.  Cells were cultured in DMEM without L-glutamine and 
sodium pyruvate, combined with 10% FBS, 1% nonessential amino acids and 1% 
Pen/Strep/Amp-B.  Cells were allowed to attach during the lag phase (5 hours) 
and then media was replaced with FBS-free media.  This is because insulin is 
present in FBS, which could possibly alter the results.  Cells were subsequently 
allowed to grow in FBS-free media for 3 days.  
Insulin or an insulin conjugates were dissolved in FBS-free media at 0.5 
mg/ml and sterile filtered with a 0.2 µm filter.  Dilutions were performed to 
achieve 1 μg/mL, 10 μg/mL, and 100 μg/mL.  Cells were then exposed to insulin 
or an insulin conjugate sample for 3 hours. Samples included insulin, 1K 
PEGylated insulin (1KPI), 2K PEGylated Insulin (2KPI), and 5K PEGylated 
Insulin (5KPI). 
A MultiTox-Glo Multiplex Cytotoxicity Assay was used to determine 
cytotoxicity and cell viability by measuring two different protease activities.  Cell 
viability was measured by using Gly-Phe-7-amno-4-trifluoromethyl coumarin (GF-
AFC), which is cleaved by enzymes present only in live to release causing the 
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fluorescent compound.  A second luminogenic compound, alanyl-alanyl-
phenylalanyl-aminoluciferin (AAF-Glo™), measured cytotoxicity.  AAF-Glo™, 
measure proteases from dead cells after they have lost membrane integrity [16]. 
A schematic of this reaction scheme is shown in Figure 5.2.  To implement this 
assay, a 50 µL sample of the GF-AFC reagent was added to each individual 96-
well plate.  The solution was briefly agitated on a shaker plate to ensure 
homogeneity and then incubated with the cells for 2 hours at 37°C. During this 
time, the 96-well microplate was protected from light.  After 2 hours, the plate 
was measured at an excitation of 400 nm and an emission of 505 nm. 
Subsequently, AAF-Glo™ was added, the sample was mixed using an orbital 
shaker, and  then allowed to incubate for 15 minutes at room temperature.  This 
component was excited at 485 nm and emitted at 520 nm. 
5.3. Results 
5.3.1. Transport and TEER 
 Cultured epithelial cells have been successfully used as tools for the 
screening of drug permeation and transport during the last two decades.  Caco-2 
cells display many of the characteristics of the human epithelial layer; including 
the production of a number of physiologically relevant enzymes, a brush border, 
and the formation of tight junctions.   HT29-MTX cells produce mucus and are 
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highly permeable. The combination of these two lines allows for the adjustment of 
permeability while also having a mucus layer; creating a more physiologically 
relevant model [7]. 
A preliminary assessment of the transport characteristics of the PEGylated 
insulin conjugates in the presence of microparticles was performed using the 
Caco-2: HT29-MTX monolayer as described above.  Cumulative amount with 
respect to time is shown in Figure 5.3 and permeability is shown in Table 5.1. 
The apparent permeability for PI conjugates was approximately 1/3 that of the 
permeability of insulin.  This is to be expected as both hydrophilic drugs and 
peptides are known to distribute poorly in the cellular epithelium and therefore it 
is assumed that these drugs travel through the water-filled pores of the 
paracellular pathway  [9].  Because PEG is a hydrophilic molecule, a diminished 
permeability is expected. We can see that the PEGylation did decrease the 
permeability of the insulin. In addition, permeability appeared to decrease with 
increasing chain length.  These results do not account for the enzymes that are 
primarily responsible for degrading insulin; elastase, trypsin and α-chymotrypsin, 
and thus do not adequately demonstrate the value of the PEGylation of insulin  
[10]. 
Finally, TEER was evaluated.  This measurement can be correlated to the 
integrity of the tight junctions in the cellular epithelium.  The decrease of the 
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TEER value indicates disruption of the tight junctions and subsequently that 
transport is occurring between the tight junctions.  A decrease in TEER has been 
previously demonstrated with insulin in the presence of microparticles.  There is 
no significant difference between PEGylated insulin and insulin in the presence of 
P(MAA-g-EG); Figure 5.4.  There is also no significant difference between insulin 
without particles and insulin or PEGylated insulin with microparticles.  In addition, 
insulin without particles displays the same basic trend.  It is believed that this 
occurs because changing the media may wash away a portion of the mucus layer 
[7]. 
5.3.2. Cytocompatability 
 Cell viability and cytotoxicity were studied with murine fibroblasts, as 
fibroblasts cells are commonly found in many areas of the body.  Cell viability and 
cytotoxicity are typically inversely correlated [17].  As can be seen in Figure 5.5, 
there was no measurable difference in the number of live cells for insulin or the 
PEGylated insulin conjugate at 1 ug/mL.  Note that the concentrations involved in 
this study are supersaturated amounts as normal blood concentrations are more 
than 100 times smaller.  At 10 µg/mL, there is a statistical decrease in the cell 
viability for the 5KPI over unconjugated insulin, and at 100 µg/mL there is a 
statistical difference for both the 5KPI and 2KPI. It is believed that the cell 
viability is slightly lower with these formulations, as the 5KPI is the hardest to 
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purify with membrane cutoff filtration because the PEG can clog the pores of the 
filter and prevent reactants from being removed. Subsequently, the 1KPI is 
easiest to purify as it is less likely to clog the pores of the membrane cutoff filter.  
With respect to cytotoxicity, all samples except 5KPI had fewer dead cells than 
cells untreated with insulin. 
5.4. Conclusions 
Although PEGylation caused a reduction in permeability, the insulin remained 
able to cross the intestinal epithelium.  It is not believed that one will see the true 
benefits of PEGylation in cell culture, as repeated washings serve to reduce the 
presence of mucus and proteolytic enzymes.  As such, further study is needed to 
determine benefits.    
TEER results showed that there was no major difference between insulin 
in the presence of microparticles and PEGylated insulin, and that any loss in 
resistance created by microparticles recovered in less than 3 hours.  It is known 
that washing the cells will wash away the mucin layer [5].  The reduction and then 
return of the TEER values may also be related to the washing away and 
replacement of mucin, as a similar trend was also seen in earlier studies [11].   
Finally, the cell viability of the PEGylated insulin was evaluated when 
exposed to fibroblasts. No changes in cell viability were observed until 1000 
times the concentration normally seen in the blood. As such, one can conclude 
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that PEGylated insulin does not affect cell viability of 3T3 fibroblasts at 
physiologic concentrations. 
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Figure 5.1. Schematic of transepithelial resistance (TEER) measurement.  
Resistance is measured across apical and basolateral chamber. 
Decreased resistance indicates disruption of cell tight junctions. 
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Figure 5.2. Schematic of a live/dead cell assay. The fluorogenic GF-AFC 
Substrate can enter live cells, where it is cleaved by the live-cell 
protease to release the AFC molecule.   AAF-Glo™ cannot enter live 
cells, but can be cleaved by the protease activity released by dead 
cells to generate aminoluciferin, which is detected by measuring 
luminescence.  
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Figure 5.3. Cumulative transport(ng) across the 50:50 Caco-2/HT29-MTX co-
culture.  Insulin or PEGylated insulin transport in the presence of 
P(MAA-g-EG) microparticles, n=5.  Key: insulin (), 1KPI (X), 2KPI 
(Δ), and 5KPI (). 
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Figure 5.4. Changes in TEER in the presence of P(MAA-g-EG) microparticles 
and insulin, 1KPI, 2KPI or 5KPI.  Each data represents the mean ± 
SD, n=3. Key: insulin (), 1KPI (X), 2KPI (Δ), 5KPI (), and insulin 
without particles (+). 
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Figure 5.5. Fraction of viable cells with respect to cells untreated with insulin. 
Concentrations are 10, 100, 1000 times greater than what would 
normally be seen by systemic fibroblasts.  Data represents the mean 
± SD, n=5. Key: insulin (), 1KPI (), 2KPI (), and 5KPI (). 
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Table 5.1. Apparent cellular permeability of insulin and insulin conjugates in the 
presence of microparticles. The average ± one SD was recorded, 
n=5. *P<0.05 when compared to insulin. 
 
Conjugate Papp x 109 (cm/s) 
Insulin 9.17 ± 2.20 
 PEG (1000) Insulin 3.28 ± 0.88* 
PEG (2000) Insulin 2.90 ± 0.86* 
PEG (5000) Insulin 2.44 ± 0.06* 
 
 
 
 92 
5.5. References 
1. Gad, S. C. Toxicology of the Gastrointestinal Tract. Target Organ 
Toxicology  Series (A. W. Hayes, J. A. Thomas and D. E. Gardner, eds.) 
2007. Boca Raton CRC Press, Boca Raton, FL. 
2. Ayabe, T., Satchell, D. P., Wilson, C. L., Parks, W. C., Selsted, M. E., and 
Ouellette, A. J. Secretion of microbicidal alpha-defensins by intestinal 
Paneth cells in response to bacteria. Nat Immunol, 2000. 1, 113-118. 
3. Hidalgo, I. J., Raub, T. J., and Borchardt, R. T. Characterization of the 
human colon carcinoma cell line (Caco-2) as a model system for intestinal 
epithelial permeability. Gastroenterology, 1989. 96, 736-749. 
4. Artusson, P., and Karlsson, J. Correlation between oral drug absorption in 
humans and apparent drug permeability coefficients in human intestinal 
(Caco-2) cells. Biochem Biophys Res Commun, 1991. 175, 880-885. 
5. Walter, E., Janich, S., Roessler, B. J., Hilfinger, J. M., and Amidon, G. L. 
HT29-MTX/Caco-2 Co-cultures as an in vitro model for the Intestinal 
Epithelium: In vitro- in vivo correlation with permeability data from rats and 
humans. J Pharm Sci, 1996. 85, 1070-1076. 
6. Lesuffleur, T., Roche, F., Hill, A. S., Lacasa, M., Fox, M., Swallow, D. M., 
Zweibaum, A., and Real, F. X. Characterization of a mucin cDNA clone 
 93 
isolated from HT-29 mucus-secreting cells. J Biol Chem, 1995. 270, 
13665-13673. 
7. Hilgendorf, C., Spahn-Langguth, H., Regardh, C. G., Lipka, E., Amidon, G. 
L., and Langguth, P. Caco-2 versus Caco-2/HT29-MTX co-cultured cell 
lines: Permeabilities via diffusion, inside- and outside-directed carrier-
mediated transport. J Pharm Sci, 2000. 89, 63-75. 
8. Balimane, P. V., Chong, S., and Morrison, R. A. Current methodologies 
used for evaluation of intestinal permeability and absorption. . J Pharmacol 
Toxicol Methods, 2000. 44, 301-312. 
9. Artusson, P., Palma, K., and Luthmanb, K. Caco-2 monolayers in 
experimental and theoretical predictions of drug transport. Adv Drug 
Deliver Rev, 2001. 46, 27-43. 
10. Khafagy, S., Morishita, M., Onuki, Y., and Takayama, K. Current 
challenges in non-invasive insulin delivery systems: A comparative review. 
Adv Drug Deliver Rev, 2007. 59, 1521-1546. 
11. Wood, K. M., Stone, G., and Peppas, N. A. Wheat Germ Agglutinin 
Functionalized Complexation Hydrogels for Oral Insulin Delivery. 
Biomacromolecules, 2008. 9, 1293-1298. 
 94 
12. Wood, K. (2006). Molecular Design of Advanced Oral Protein Delivery 
Systems Using Complexation Hydrogels. The University of Texas at 
Austin. 
 95 
 
CHAPTER 6 
IN VIVO INTESTINAL TRANSPORT 
6.1 Introduction 
In recent years, a large number of interest groups have questioned the 
use animals in biomedical research. They believe that the knowledge gained 
through animal study is not sufficient to justify pain, distress, and premature 
death suffered by these laboratory animals.  Animal activists believe that through 
computer modeling and cell and tissue culture, animal studies can be completely 
eliminated.  While cell culture and computer modeling are powerful research 
tools, the need for animal studies is undeniable as these types of studies simply 
cannot account for all of the variables present in an in vivo setting. Computer 
modeling and cell culture are useful as screening tools to predict whether ideas 
show promise. This process reduces the number animals studies necessary to 
make important research decisions by helping scientists evaluate design 
conditions. 
Currently, mice and rats are used in about 95% of the animal research 
studies done in the US.  Rats are primarily used as toxicology and neurological 
models and provide primary culture cells [1].  According to Harlen Sprague-
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Dawley, a company that specializes in breeding rats for animal testing 
applications, Sprague-Dawley rats are multipurpose albino rats, typically selected 
for their calmness and ease of handling.  Sprague-Dawley rats were chosen as 
they are a good choice for drug delivery models, due to the fact that the 
esophagus enters the stomach at a lesser curvature through a fold of tissue in 
the stomach, eliminating the ratʼs ability to vomit.  In addition, Sprague-Dawley 
rats lack a gall bladder. Healthy, non-diabetic rats due to a recent requirement by 
a number of animal care and use committees as well as a number of journals to 
control humane testing. 
One major factor affecting drug availability is the supply of the drug at the 
absorptive region (i.e. the small intestine).  Carriers, such as P(MAA-g-EG) are 
designed to delivery proteins to the absorption site.  However, once the protein is 
released from the polymer, it must be soluble in gastric fluids, avoid proteolytic 
degradation, and be able to transport across the cellular epithelium.  Once a drug 
crosses the cellular epithelium, it will enter the liver. If it the insulin is not filtered 
during first pass metabolism, it then enters the blood stream, which carries it to 
the rest of the body. The drug also may be taken up by other body cells or broken 
up by enzymes as it travels through the body [2].  Directly measuring the amount 
of drug in the blood is known as bioavailability, while measuring the physiologic 
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effects of the drug such as measuring glucose levels after delivering insulin is 
known as pharmacological availability (PA) [3]. 
 In the studies that follow, insulin and PEGylated insulin was injected 
subcutaneously into Sprague-Dawley rats, and the resulting glucose change was 
measured as a function of time. This was done to ensure that the PEGylated 
insulin conjugates are biologically active.  Solutions of insulin and each insulin 
conjugate were then delivered directly to the small intestine to study insulin 
absorption. 
As bioavailability (the amount of insulin in the blood) does not always 
correlate to pharmacological availability (change in blood glucose levels), both 
pharmacological availability and bioavailability were examined. 
6.2. Methods and Materials 
Prior to experimentation, LysineB29 PEGylated insulin in 3 chain lengths; 
1000 (1kPI), 2000 (2kPI), and 5000 (5kPI) was prepared, purified, and vacuum 
dried as discussed in Chapter 4. 
6.2.1. In situ Absorption Studies 
This research was performed at Hoshi University and complied with the 
regulations of the Committee on Ethics in the Care and Use of Laboratory 
Animals.  Male Sprague-Dawley rats weighing 180-220 g were purchased from 
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the Tokyo Laboratory Animal Sciences Company.  After purchase, rats were 
housed in climate controlled rooms with a temperature of 23.1 ± 1°C and a 55 ± 
5% relative humidity level and were allowed free access to food and water.  24 
hrs prior to experimentation, rats were fasted, yet were allowed free access to 
water.  Just prior to experimentation, rats were weighed and anesthetized with 50 
mg/kg pentobarbital (Dainippon Pharmaceutical Company, Osaka, Japan) with 
additional injections (12.5 mg/kg) administered every hour to maintain 
anesthesia.  The rats were restrained in the supine position on a temperature-
controlled plate. 
A small incision was made along the abdominal midline to expose the 
inferior portion of the illeum.  A section proximal to ileocecal junction segments 
(10 cm length) was cannulated with polypropylene.   The cannulated segment 
was washed with 20 mL of 37°C prewarmed saline delivered at 1 mL/minute 
using a parastaltic pump.  The cannulae were removed and the intestinal 
segments were tightly closed.  The rats were allowed to recover for at least 30 
minutes to allow for the injury-induced elevated blood glucose levels to stabilize.  
A 50 IU/kg dose of 1KPI, 2KPI, 5KPI or insulin suspended in PBS was 
administered to a 6 cm section of the 10 cm pretreated intestinal segment.   0.2 
mL aliquots of blood were drawn directly from the jugular vein at 0, 5, 10, 15, 30, 
60, 120, 240 minutes using 1 mL pretreated heparanized syringes (Tuberculin®, 
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Becton-Dickenson, Franklin Lakes, NJ). These syringes were prepared 1 day 
prior to the experiment by aspirating heparin through each syringe, completely 
expelling the heparin and then allowing the syringe to dry.  The blood glucose 
was immediately measured with a Novo Nordisk Glucose Meter (Johnson & 
Johnson, Langhorn, PA) and then centrifuged at 13,000 RPM for 1 minute to 
separate whole blood from plasma. The plasma insulin concentration was then 
analyzed with ELISA immediately following the experiment (Invitron, Monmouth, 
UK).  The bioavailability was calculated relative to the subcutaneous (s.c.) 
injection as described below. 
The subcutaneous bioavailability was determined by dissolving PI or 
insulin in PBS at 1 IU/kg bodyweight. To maintain the same physical conditions, 
the ileal loop surgery was performed on the rats that received subcutaneous 
insulin. 
In order to determine the pharmacodynamic effect, the area above the 
normalized glucose versus time curve (AAC) was calculated by determining the 
area below the axis between the resultant curve and 1.  This was calculated 
using the trapezoidal rule. In this case the s.c. AAC was determined from the 
subcutaneous administration of 1.0 IU/kg insulin. Pharmacological availability 
was calculated according to the equation that follows: 
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  (9.1) 
While pharmacological availability reflects the action of insulin on the 
glucose level of the bloodstream, it often does not directly correlate with the 
amount of insulin in the blood.  Thus, it is also important to measure the amount 
of insulin in the bloodstream over time, or bioavailability [4, 5]. To determine the 
change in insulin conjugation, the initial concentration was subtracted from the 
measured insulin concentrations.
 
In order to determine the bioavailability (F) of PEGylated insulin, the area 
under the insulin concentration curve versus time (AUC) from 0-240 minutes was 
calculated using the trapezoid rule for both subcutaneous and intestinal delivery 
and normalized by dosage as shown in the following equation: 
  
 (9.2) 
When studying bioavailability, PEGylated insulin in solution delivered to 
the small intestine was compared to subcutaneously delivered insulin.  The 
plasma peak level (Cmax) and the time taken to reach the plasma peak level 
(Tmax) were determined from the plasma insulin concentration versus time curve.  
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6.3 Results and Discussion 
6.3.1 Influence of PEGylation in Subcutaneous Administration  
Probably one of the most significant characteristics of PEG is that it is 
soluble in both polar and nonpolar solvents, which provides a wide variety of 
possible solvents. PEG is a unique molecule, as it has been shown that when 
conjugated to a protein, it transfers its properties to the protein molecule [6, 7]. 
Each ethylene oxide molecule binds to 2-3 water molecules, effectively leading to 
a “shell” that is formed around the insulin [8].  This “shell” causes an increase in 
protein solubility and helps to protect the protein from the approach of other 
polymers, both natural and synthetic [9].   It has also been shown that the 
modification of proteins with PEG creates an increase in the circulating life of the 
protein in the bloodstream and also is known to reduce the proteinʼs 
immunogenicity and antigenicity [6]. The increased circulating life is credited to 
masking of ligands as well as antigens recognized by cellular receptors via steric 
hindrance [10].  It follows that this trait also prevents proteolytic degradation, 
which has been demonstrated in vitro with elastin and pepsin [8, 11].   
Despite all of these advantages, limited and conflicting information exists 
with respect to PEGylated insulinʼs pharmacological availability.  One study 
shows a significant improvement with insulin PEGylated in two different locations 
(B1Phe and B29Lys) using a chain length of 750; while a second study shows no 
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statistical difference between PEGylated insulin (chain length: 750 at lysB29) and 
insulin following s.c. injection [11, 12].  These conflicting results along with the 
differences in chain length and conjugation chemistry necessitated a s.c. 
evaluation of the efficacy of the PEGylation. 
6.3.2 Influences of PEGylation on Insulin in Subcutaneous Delivery 
Figure 6.1 depicts the changes in blood glucose from subcutaneously 
delivered insulin and PEGylated insulin while Table 6.1 depict the AAC, a value 
of the hypoglycemic response and PA, a value that compares the AAC of the 
insulin conjugates to that of insulin.  To simulate the stress and subsequently the 
glucose response that occurs during the closed loop study, the closed loop 
surgical procedure was performed on each subject. Both insulin and 1KPI were 
effective at reducing the glucose levels below baseline throughout the testing 
period. The 2KPI insulin had a lower PA, but also was able to maintain the 
glucose level below baseline.  Finally, the 5KPI had the least effect of the 
PEGylated insulin samples on blood glucose levels. 
We expect this occurred because the 1000 PEG chain may limit the 
resulting decreased clearance and degradation, while allowing the insulin to 
retain its bioactivity.  In addition, literature has shown that PEGylation with this 
molecular weight further serve to limit aggregation, fibrillation and degradation 
due to the non-specific steric hindrance of the intermolecular interactions that 
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occur during fibrillation [6, 13].  As the molecular weight increases, the PA 
decreases suggesting that longer PEG chains may impede the binding of insulin 
with its receptor. 
6.3.3 Influences of PEGylation on Insulin in Intestinal Closed-Loop Delivery 
The amount of insulin in solution and the reduction in glucose was 
measured for PEGylated insulin as well as unconjugated insulin (Figure 6.2 and 
Figure 6.3). The bioavailabilities and pharmacological availabilities of insulin and 
PEGylated insulin in solution were determined when delivered directly to the 
intestine (Tables 6.2 and Table 6.3).  To account for the fact that healthy rats 
were used and the glucose response to injury (such as that associated with the 
intestinal operation or the needle stick required for the blood draw), each 
measurement was normalized by the initial insulin value. 
 It was discovered that insulin in solution had the lowest AUC and 
bioavailability.  In addition, the elevation in insulin concentration returned to 0 
after 2 hrs.  1KPI had a bioavailability that was 1.2 times larger than 
unconjugated insulin, while 5KPI was 1.4 times larger.  2KPI had the largest 
bioavailability, the value was 2.9 times larger than unconjugated insulin with a 
bioavailability of 3.05.  2KPI also had the highest maximum concentration; 72.58 
μg/mL.  This is due to the fact that PEGylation may prevent the binding of the 
antibody, thus skewing the ELISA results [6, 12].  This apparent reduction in 
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concentration of PEGylated insulin when measured with ELISA has occurred in 
studies with other protein types.  The generally accepted cause behind this 
reduction is that the PEG molecule restricts the accessibility of the monoclonal 
antibody to the binding domain on the insulin  [14].   
Figure 6.2 depicts the glycemic response following the administration of 50 
IU/kg insulin or PI to the small intestine, while Table 6.3 depicts the AAC and the 
PA.  Unconjugated insulin at this dosage yielded a limited hypoglycemic 
response, indicating that only a limited amount of insulin is naturally absorbed by 
the ileal segment of the small intestine. When PI was delivered directly to the 
ileum, all PEGylated insulin conjugates improved the blood glucose level. This 
result was surprising, as it was shown that 2KPI and 5KPI had a significantly 
reduced pharmacologic availability. 2KPI had the greatest hypoglycemic effect 
with an AAC of 82.3% and a PA of 3.65%.  This conjugate effectively increased 
the PA by 2.8 times.  In addition, the 2KPI continued to produce a significant 
hypoglycemic effect at 4 hours, almost 3 hours after unmodified insulin has 
exceeded baseline. 
Glucose level measurements are believed to be a more reliable measure 
of the effects of PEGylated insulin in the body as glucose directly measures the 
bodyʼs reaction to the PEGylated insulin that it receives. Although limited glucose 
depression was seen with unconjugated insulin, there was some measurable 
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increase in insulin concentration over the time duration. The pharmacological 
availability of 1KPI and 5KPI remained above 0 throughout the time period.  
However, very little reduction in glucose occurred with the 5KPI.  This is believed 
to have occurred because when 5KPI was injected subcutaneously, it was shown 
to have limited bioavailability and pharmacological availability.  Due to the altered 
activity of the conjugate, even if it is shown to be present in the blood, this does 
not demonstrate its effectiveness in reducing glucose levels.  1KPI was not in the 
bloodstream at a pharmacological availability as high as 2KPI, but it had the 
highest levels when delivered subcutaneously. This led to the result that although 
there was not a tremendous amount of 1KPI insulin in the blood, the high 
pharmacological availability led to a reduction in blood glucose that always 
remained above 0.  Finally the 2KPI had by far the highest peak concentration 
(Cmax), with an average of 72.58 ug/mL when delivered orally. Additionally, 2KPI 
had blood insulin concentrations that remained above 0 for the duration of the 
study, and were significantly higher than that of insulin and the other conjugates. 
This result translates to the fact that the 2KPI conjugate was able to depress the 
glucose levels over the course of the study and increase the pharmacological 
availability over insulin by 2.8 times.  These results are believed to have occurred 
because the 2KPI optimizes the effect of PEG on the insulin; allowing it to be 
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protected from proteolytic degredation, yet the chain is sufficiently short to avoid 
inhibiting the action of insulin on glucose levels. 
The general improvement in the efficacy of PEGylated insulin presumably 
occurred for two reasons.  PEG-insulin is extremely soluble with respect to insulin 
and it is known that solubility improves diffusion and subsequently transport 
across the epithelium.  PEGylation limits degradation, aggregation and fibrillation, 
which means it protects the protein against enzymes in the GI tract, and it limits 
the size of the insulin (and subsequently the hydrodynamic radius) by means of 
preventing aggregation and fibrillation [6, 12].  The reason the 2KPI outperformed 
the other molecular weights is likely because it was large enough to provide 
sufficient protection from proteolytic enzymes without blocking active sites. 
These results may further be explained through results obtained in 
literature.  A number of in situ experiments using insulin have been performed 
which demonstrate that insulin can be uptaken by the small intestine [15, 16].  
The use of PEGylated protein delivery was previously validated in a closed-loop 
intestinal study, which was performed with 2K PEGylated calcitonin.  The 
biological marker for this protein, calcium, was greatly reduced when PEGylated 
so much so that the AAC of PEGylated calcitonin was 2.2 times that of calcitonin 
itself [17].  
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6.4 Conclusions 
 These studies demonstrate that 2KPI insulin is the best choice for the oral 
delivery of PEGylated insulin, as it leads to the greatest increase in plasma 
insulin and the greatest glucose depression when delivered orally.   
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Figure 6.1. Changes in the blood glucose level following the subcutaneous 
delivery of 1 IU/kg insulin or PEGylated insulin in fasted Sprague-
Dawley rats. Samples include insulin (), 1KPI (), 2KPI(∆) and 
5kPI (X).  Each value represents the average ± SD, n=3. 
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Figure 6.2. Changes in blood glucose following the administration of 50 IU/kg 
PEGylated insulin in the small intestine of fasted Sprague-Dawley 
rats.  Key: insulin (), 1KPI (), 2KPI(∆) and 5kPI(X). 
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Figure 6.3. Plasma insulin concentration after administering 50 IU/kg insulin or 
PEGylated insulin solution to the small intestine, n=3. Key: insulin 
(), 1KPI (), 2KPI(∆) and 5kPI(X).   
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Table 6.1. The area above the curve and the pharmacological availability of 
subcutaneously delivered insulin conjugates. The mean ± SD is 
recorded, n=3. 
 
 AAC   
(% glucose reduction) 
PA  
(%) 
Insulin 45.05 ± 16.56 n/a 
1KPI 46.61 ± 20.60 103.47 ± 45.73 
2KPI 18.59 ± 19.63 41.26 ± 43.26 
5KPI 8.59 ± 12.16 19.08 ± 26.98 
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Table 6.2. Intestinal absorption results based on insulin concentration.  This 
chart depicts the maximum concentration (Cmax), the time at which 
the maximum concentration was measured (Tmax), the area under the 
insulin curve (AUC) and the bioavailability (BA) of 50 IU/kg orally 
delivered insulin and PEGylated insulin solution.  The mean ± SD is 
recorded, n=3-4. 
 
 Cmax  
(μg/mL) 
Tmax AUC  
(ug*h/mL) 
BA  
(%) 
Insulin    12.61 ± 9.85 1.064 ± 0.83 
1KPI 17.16 ± 11.70 26.67 ± 29.30 15.39 ± 22.73 1.30 ± 1.92 
2KPI 72.57 ± 93.04 15.00 ± 13.23 36.16 ± 39.59 3.052 ± 3.34 
5KPI 14.19 ± 13.06 8.33 ± 5.77 17.52 ± 23.45 1.48 ± 1.98 
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Table 6.3. Area above the curve and pharmacological availability of insulin and 
PEGylated insulin delivered directly to the small intestine, n=3-4. 
 
 AAC (% glucose reduction) PA (%) 
Insulin 12.61 ± 9.85 0.56 ± 0.44 
1KPI 12.81 ± 14.59 0.56 ± 0.65 
2KPI 82.30 ± 32.50 3.65 ± 1.44 
5KPI 3.34 ± 4.37 0.37 ± 0.48 
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CHAPTER 7 
DEVELOPMENT OF POLYMERS FOR PEGYLATED INSULIN 
 
7.1 Introduction 
 Hydrogels are hydrophilic network polymers that swell in water while 
maintaining structural integrity by either chemical or physical cross-linking.  
Physical cross-linking may include chain entanglement or weak molecular 
associations, such as hydrogen bonding and van der Waals interactions.  It has 
been shown that many types of hydrogels can be tailored to react to a wide 
variety of stimuli including pH, both anionic and cationic, temperature, light, 
magnetic field, electric current and ultrasound [1].   
 PH sensitive hydrogels have demonstrated their usefulness in drug 
targeting, most notably oral drug delivery of proteins. In our laboratory, we have 
developed a methacrylic acid based polymer with PEG grafts for oral drug 
delivery applications.  These poly(methacrylic acid-g-ethylene glycol) (P(MAA-g-
EG)) polymers are anionic complexation hydrogels. At a pH of approximately 2, 
they have a small mess size due to hydrogen bonding between the carboxylic 
acid group on the methacrylic acid and the oxygen on the ethylene oxide unit of 
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the PEG grafts.  When the pH is increased to approximately 7, the methacrylic 
acid is ionized and the electrostatic repulsion allows water to enter the hydrogel, 
causing the mesh size to increase.  This phenomenon is compatible with the 
conditions of the digestive system. Under the low pH conditions of the stomach, 
the polymer is complexed and the mesh size is small; effectively protecting the 
protein from acid hydrolysis. When the drug reaches the small intestine, which 
has a pH above 7, the polymer expands and releases the insulin into the small 
intestine where it is to be absorbed [2, 3].   
Laboratory results have demonstrated the usefulness of P(MAA-g-EG) 
hydrogels for oral drug delivery.  The ionized methacrylic acid has been shown to 
bind to calcium; which can serve to reduce proteolytic degradation.  It has been 
shown that P(MAA-g-EG) is mucoadhesive, and thus improves residence time 
through adhesion to the mucus layer of the intestinal wall.  Bioavailabilities up to 
12.8% have been achieved with the P(MAA-g-EG) delivery system  [4]. This 
result was achieved with particles <43 μm has been demonstrated that a 1:1 
MAA:EG molar feed ratio yields optimal loading and release characteristics for 
unmodified insulin [2]. 
 One drawback to the P(MAA-g-EG) hydrogel system is that upon release 
from the polymer, the insulin is exposed to the proteolytic enzymes in the small 
intestine which serves to degrade the insulin.  It has been shown that 
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poly(ethylene glycol) (PEG) conjugation to insulin also helps avoid proteolytic 
degradation and chemical instability, as well as improve solubility.  PEG is a 
flexible, hydrophilic polymer; in an aqueous solution, 2-3 water molecules per 
ethylene oxide unit will coordinate around the polymer- effectively creating a 
hydration sphere that can protect the PEG and molecules associated with it  [5, 
6].  
 Drug loading and release from hydrogels is typically diffusion mediated.  In 
the past, our laboratory sought to optimize the mesh size, and subsequently the 
loading and release characteristics of the proteins being evaluated by altering 
cross-linking density and solvent ratios.  However, in the case of PEGylated 
insulin, a study in a thesis by Tony Tuesca at Drexel University demonstrated 
that significantly altering mesh size did not alter loading and release 
characteristics of PEGylated insulin.  Past studies have also shown that the 
ethylene oxide unit on the PEG grafts hydrogen bonds with the MAA in the 
hydrogel [7].  It is expected that the ethylene oxide units on PEGylated insulin will 
respond similarly. Because of this phenomena as well as the fact that mesh size 
had a negligible affect on loading, it is hypothesized that optimizing the PEG graft 
density is essential for optimizing the loading and release characteristics of 
PEGylated insulin in P(MAA-g-EG).  This theory was evaluated by comparing the 
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loading and release characteristics of MAA with no grafts to those with varying 
graft densities. 
7.2 Methods 
7.2.1. Synthesis of P(MAA-g-EG) Hydrogels 
 Poly(Methacrylic acid-g-ethylene glycol) (P(MAA-g-EG)) polymers were 
synthesized using free radical polymerization.  A 1:1 molar feed ratio of 
methacrylic acid (MAA):PEG monomethylether monomethacrylate (PEGMMA) 
was added to an equal mass of 50 wt% solution of ethanol in water.  
Tetraethylene glycol dimethacrylate (TEGDMA) was used as the crosslinker and 
was added at a ratio of 1 mol% of total monomer.  Both TEGDMA and PEGMMA 
were obtained from Polysciences Inc (Warrington, PA). The initiator used was 1-
hydroxycyclohexyl phenyl ketone (Irgacure® 184), which was obtained from 
Fisher Sciences (St. Louis, MO).  The ratios mentioned above are optimized for 
unconjugated insulin.  The 1:1 MAA:EG hydrogel was compared to a hydrogel 
without grafts, and two with fewer grafts at a 3:1 MAA:EG ratio. There were 2 
different PEG graft lengths studied with the 3:1 polymer PEG (1000) and PEG 
(2000).  A recipe for each polymer studied is shown in Appendix A.2.  After the 
films were synthesized, they were washed twice a day for 7 days and then dried 
in a vacuum oven.  
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7.2.2. Complexation Hydrogel Loading  
 Drug loading was accomplished by equilibrium partitioning insulin (MP 
Biomedicals, OH)  or PEGylated insulin into the p(MAA-g-EG) microparticles [2].  
A 10 mg insulin sample or a molar equivalent PI sample was dissolved in 2.5 mL 
0.1 N HCL in a flask coated with Sigmacote®. The solution was normalized with 
2.5 mL 0.1 N NaOH and 15 mL of PBS was added to stabilize pH at 7.4. A 140 
mg sample of P(MAA-g-EG) microparticles was added and allowed to incubate 
with the insulin for 2 hours under constant stirring. After two hours, 10 mL of 0.1 
N HCL was added to collapse the particles, which were allowed to incubate with 
the acid for 30 minutes.  The particles were then washed with deionized water, 
vacuum filtered with a 0.1 μm filter and analyzed immediately with reverse 
phase-HPLC. The purity of the conjugate was determined using a Waters 2695 
Separations HPLC with a Symmetry 300TM C4 column.  A sample of 20 µL was 
injected into the column, which used a mixture of 70% water with 0.1% 
trifluoroacetic acid and 30% acetonitrile with 0.08% trifluoroacetic acid as the 
solvent and a flow rate of 1 mL/min. The sample was detected at 220 nm.  
Finally, we used the concentration data obtained from HPLC results to determine 
loading.  See Appendix A.4. for a more detailed laboratory protocol. 
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7.2.3 Complexation Hydrogel Release 
 Release studies utilized conditions that were designed simulate in vivo 
intestinal conditions.  These conditions was achieved by maintaining approximate 
body temperature, which is approximated at 37°C and agitating the sample at 
100 rpm using a dissolution apparatus (Distek 2100B, North Brunswick NJ).  
Although, the pH varies greatly in the small intestine, it is commonly 
approximated using pH 7.4 PBS buffer.   Specifically, a 10 mg sample of loaded 
microparticles was placed in 20 mL of PBS solution in a siliconized flask to limit 
nonspecific adhesion.  The release was measured over a period of 2 hours by 
taking 200 μL samples and analyzing samples with RP-HPLC. Prewarmed buffer 
was used to replace the sample volume.  A more detailed protocol can be found 
in Appendix A.5. 
7.2.4 Scanning Electron Microscopy Imaging of Polymer Microparticles 
 Polymers were prepared as discussed in section 6.2.1.  Polymers were 
then dried, first by allowing them to air dry overnight and then placing them in a 
vacuum oven at 32°C.  Once dry, they were crushed and sieved to diameters  < 
43 μm.   
 Next, a thin layer of particles was placed on aluminum stubs, and the 
stubs were sputter coated with 12 nm Pt/ Pd to ensure conductivity.  These 
samples were then analyzed using the SE2 detector on the SEM (Hitachi S4500) 
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with a working distance of 32mm and an EHT of 8.00 kV.  Polymers were viewed 
at magnifications between 300x and 14,000x. 
7.2.5  Noninvasive Imaging of Insulin Being Released from P(MAA-g-EG) 
Microparticles in the Digestive Tract  
Insulin was conjugated to NHS-Cy7™ dye (GE Healthcare, Hyakunincho 
Shinjuku-ku Japan), a monofunctional fluorescent dye that absorbs at 747 nm 
and emits at 776 nm.  The conjugation was performed as follows. Insulin was 
dissolved in pH 7.4 PBS with ethylenediamenetetraacetic acid (EDTA).  A 
desalting column was used to change the buffer to 50 mM NaHCO3 buffer (pH 
7.9) and to remove salt and EDTA. The Lowry Method for protein analysis was 
used to determine protein concentration and the insulin-containing fractions were 
combined.  A second solution was prepared by dissolving NHS-Cy7™ in DMSO.  
This solution was combined with the insulin solution and reacted in the dark at 
room temperature for 14 hours.  A15 µL aliquot of triethyleneamine was added to 
the solution, which was then reacted for an additional 30 minutes.  The solution 
was then dialyze to remove any unreacted dye and finally lyophilized. Drug 
loading of the tagged insulin was then completed as described above.  Equimolar 
amounts of Cy7™-insulin loaded in 1:1 P(MAA-g-EG) or Cy7™-insulin were 
loaded into gel capsules.   
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Prior to study, rats were fasted for 48 hours to ensure that the intestine 
was clear of obstructions that may inhibit imaging.  Gel capsules were 
administered to restrained, shaved, male Sprague-Dawley rats.  For this study, 
animals were not anesthetized. The abdomen of the rat was excited at 747 nm 
with the LB940 Mirthras Multimode Reader (Berthold Technologies, Bad Wildbad, 
Germany).  Cy7™ insulin emitted around 776 nm, which was imaged with the 
NightOwl LB981 camera (Berthold Technologies,  Bad Wildbad, Germany).  At 
this wavelength, the camera was able to penetrate the body tissue to image the 
fluorescent dye directly.  The camera setup, which is depicted in Figure 7.11, was 
unique in that it is located inside a cabinet.  The placement of the camera was 
computer controlled by IndiGo™software and motor driven, with a reproducibility 
of ± 100 μm.   
Images were taken at 30, 60 and 120 minutes.  Rats were restrained while 
the image was being taken and allowed back in the cage between imaging 
sessions. During the study, rats were placed in separate cages to avoid being 
injured by other rats while in a stressed and weakened state. 
 125 
7.3 Results and Discussion 
7.3.1 Development of P(MAA-g-EG) Carriers for PEGylated Insulin 
 P(MAA-g-EG) carriers were developed for the PEG insulin conjugates. As 
it was believed that the interactions between the hydrogel and PI would be 
governed by hydrogen bonding, the effects of the grafted PEG chain density and 
length were evaluated.  Polymer formulations included the formulation that has 
been optimized for unconjugated insulin; 1:1 MAA:EG ratio with PEG(1000) 
grafts, a P(MAA) polymer, and two polymers with a 3:1 MAA:PEG ratio; one with 
a PEG graft length of 1000 and the other with a graft length of 2000, as shown in 
Figure 7.1. Polymers were crushed to a diameter of < 43 μm, because it has 
been shown that optimal loading and results of insulin are achieved with 
polymers in this size range.  
 Samples concentrations were determined with HPLC to calculate loading 
efficiency and release.  Loading efficiency was defined as the difference between 
the initial (Co) and final concentrations (Cf), using the initial concentration to 
normalize the data as shown in the following equation: 
 
  (7.1) 
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 For unconjugated insulin, prior to the addition of acid, and subsequent 
collapse of the particles, 1:1 P(MAA-g-EG) yielded the best loading results.  The 
amount of insulin loaded into the polymer carriers decreased with a decreasing 
PEG graft density; with almost no loading in the P(MAA) particles. When 
PEGylated insulin was loaded into hydrogels, significant loading occurred prior to 
the collapse of the gels.  This loading behavior is believed to occur because of 
diffusion.  
After the particles were collapsed through the addition of acid, the amount 
of unconjugated insulin loaded decreased as some of the insulin was forced out 
of the polymer when the PEG was collapsed.  In contrast, the loading results for 
PEGylated insulin improved upon the addition of acid. Specifically, once acid was 
added, hydrogen bonding led to loading percentages greater than 96% in all 
cases except in the 1:1 MAA:EG polymer. It is believed that the decreased 
loading for the 1:1 MAA:EG polymer was due to steric hindrance of the hydrogen 
bonds. 
 The release characteristics of 2KPI was evaluated for each hydrogel and 
compared to insulin released from 1:1MAA:EG hydrogels(Fig. 4). With respect to 
the 2KPI loaded into 1:1 MAA:EG, there was  limited release.  As the density of 
the chains decreased, the release of the PEGylated Insulin increased. This result 
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agrees with earlier work, which showed that increased PEG graft density 
decreases the diffusion of a drug  [8]. 
7.3.2. SEM Analysis of P(MAA-g-EG) Formulations 
SEM images were taken of each of the polymer types at low, medium and 
high magnification to visually evaluate surface roughness and pore size of each 
of the polymers after they had been vacuum dried and crushed.  SEM images are 
show in Figures 7.5-7.10. 
1:1 MAA:EG polymers appeared rough at low magnitude and when 
viewed at a higher magnification had large, uneven striations. Both 3:1 MAA:EG 
polymers appeared considerably smoother than the 1:1 MAA:EG polymer.  The 
3:1 MAA:EG with PEG(2000) grafts appeared visibly smoother than the 3:1 
MAA:EG polymer with PEG(1000) grafts.  At higher magnification, some large 
pores were visible on the surface of the polymer with PEG(1000) grafts, while no 
pores were observed on the polymer with PEG(2000) grafts. 
When PEG grafts were used with acrylamide gels, one research group 
saw similar morphological characteristics; with fewer PEG grafts yielding a 
smoother surface.  The PEG grafts appeared to cause the formation of dense, 
yet randomly ordered chains and small pores [10].  The laboratory created a 
theory entitled “dense chain formation” to explain the macroporous network.  As 
PEG can bind up to three water molecules per ethylene oxide unit, the amount of 
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water increased with increasing amounts of PEG.  Water affected the polymer 
formation, which can form hydrogen bonds with the MAA.  The resulting 
interaction caused the polymer to form dense bundles around each PEG 
molecule.  These bundles were crosslinked in place, in this case with TEGDMA 
[10].  In the case of the 3:1 MAA:EG ratio we theorize that the “bundles” are so 
thick that they may end up taking on a smooth appearance in the cross linking 
process.  The 1:1 MAA:EG polymer appears rougher, as there are more 
numerous, but smaller bundles. 
 In work done by Torres-Lugo, the size of hydrogel microspheres created 
using a dispersion polymerization technique was shown to decrease as the PEG 
unit increased.  Similar work done by Bures also showed that poly(acrylic acid-g-
ethylene glycol) micospheres synthesized with dispersion polymerization 
decreased in size with increasing amounts of PEG  [11]. With respect to gel 
formation, this result may translate into smaller agglomerations for larger 
amounts of PEG, which also increase in striations for the polymer with the 
highest PEG graft density. 
MAA appears to have high surface roughness when viewed under low 
magnification and has regular-shaped, large pores at higher magnification. It is 
believed that these large pores can be attributed to repulsion between carboxylic 
acid groups in MAA functional monomer [12]. 
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7.3.3. Noninvasive Imaging of Insulin Being Released from P(MAA-g-EG) 
Microparticles 
Figure 7.12 shows the imaging results of insulin and insulin loaded 
particles (ILP) as it traveled through the digestive system of a Sprague-Dawley 
rat.  The concentration of the drug was qualitatively represented by the colored 
bar on the images.  For insulin without a carrier, the insulin appeared to be in the 
stomach at 30 minutes, judging by its higher proximity in the abdomen.  It then 
moved into the small intestine at 60 minutes and begins to diminish in 
concentration after 120 minutes. ILPs also appeared in the stomach at 30 
minutes, and then began to move into the intestine at 60 minutes. After 120 
minutes, the insulin concentration remained high due to the fact that the insulin 
was being protected by the microparticles as it was released into the small 
intestine.  This study provides direct evidence that P(MAA-g-EG) microparticles 
increase the residence time of insulin by protecting insulin from proteolytic 
degradation and mucoadhesion, which keep the insulin at the absorption site for 
a longer period of time [2, 4, 13]. 
7.4. Conclusions 
These studies demonstrated the successful design of a P(MAA-g-EG) 
polymer for use with PEGylated insulin.  It was shown that graft density had a 
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major effect on loading and release, rather than the number of ethylene oxide 
molecules.  This was determined through the comparison of two different PEG 
chain lengths with equimolar MAA:EG ratios.  Finally, an animal study was 
performed in which P(MAA-g-EG) microparticles were compared to insulin in 
solution.  It demonstrated the timing of the microparticles as to where they are in 
the body at what time. This information may be useful for the development and 
validation of in vitro studies.  Finally it provided direct evidence that P(MAA-g-EG) 
improves the residence time of insulin.  
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Figure 7.1. Schematic representation of polymer formulations evaluated with 
PEGylated insulin.  This figure shows schematic representations of 
each of the hydrogels studied.   
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Figure 7.2 Structure of P(MAA-g-EG) hydrogel components 
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Figure 7.3. Synthesis of P(MAA-g-EG) hydrogels.  Ingredients were combined 
and mixed thoroughly.  The contents were then purged with nitrogen 
and polymerized with UV.  Finally, polymers were washed for 7 days. 
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Figure 7.4. Release of 2KPI from P(MAA-g-EG) and P(MAA) polymers with 
respect to insulin control.  Each data represents the mean ± SD, n=3. 
Key: (X) 2KPILP 1:1 MAA:EG g-1000, () 2KPILP 3:1 MAA:EG g-
2000, () 2KPILP 3:1 MAA:EG g-1000, () 2KPILP P(MAA), and (+) 
ILP 1:1 MAA:EG.  
 
 135 
 
Figure 7.5. SEM images of 1:1 MAA:EG (top) and 3:1 MAA:EG (bottom) 
microparticles with a graft length of 1000 at low magnification.  Dried 
microparticles were placed on an aluminum stub and sputter coated 
with 12 nm Pt/Pd prior to imaging.   
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Figure 7.6. SEM Images of 3:1 MAA:EG microparticles with a graft length of 
2000 (top) and P(MAA) microparticles at low magnitude.  Dried 
microparticles were placed on an aluminum stub and sputter coated 
with 12 nm Pt/Pd. 
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Figure 7.7. A representative SEM micrograft of 1:1 MAA:EG microparticles with 
PEG 1000 grafts at high magnification. 
 138 
 
 
 
Figure 7.8. A representative SEM micrograft of 3:1 MAA:EG microparticles with 
PEG 1000 grafts at high magnification. 
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Figure 7.9. A representative SEM micrograft of 3:1 MAA:EG microparticles with 
PEG 2000 grafts at high magnification. 
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Figure 7.10. A representative SEM micrograft of P(MAA) microparticles at high 
magnification.  
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Figure 7.11. NightOWL dark cabinet configuration.  Light-tight housing (1), CCD 
NightOWL camera with motor driven vertical adjustment (2), lens (3), 
fluorescent light source with exchangeable filters (4) and supporting 
table for sample (5). 
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Figure 7.12. In vivo fluorescent imaging of insulin loaded in a P(MAA-g-EG) 
polymer compared to insulin without a carrier. Key: A was taken at 30 
minutes, B at 60 minutes and C at 120 minutes.  Insulin is shown in 
row 1 while insulin-loaded particles are shown in row 2.   
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Table 7.1. Insulin loading efficiency before acidifying the sample (%). All 
polymers aside from P(MAA) were comprised of P(MAA-g-EG). The 
length of the PEG graft is represented by g.  Samples were run in 
triplicate and the mean ± SD is recorded. *p<.05 ,**p<.01 when 
compared to loading results for insulin loading in 1:1 MAA:EG. 
p<.05, p<.01 when 2KPI loaded samples are compared to  2KPI 
loaded in 1:1 MAA:EG 
 
 
 
Insulin 
Formulation 
P(MAA) 1:1 MAA:EG g=1000 
3:1 MAA:EG 
g=1000 
3:1 MAA:EG 
g=2000 
Insulin 6.93 ±1.79** 89.16 ± 5.25 61.43 ± 18.29* 65.89 ± 6.92* 
2KPI 76.76 ± 13.83 28.04 ± 55.95 81.75 ± 17.54 54.5 ± 42.38 
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Table 7.2.  Insulin loading efficiency after acidifying the sample (%).  All 
polymers aside from P(MAA) were composed of P(MAA-g-EG). The 
graft length of each polymer is represented by g. Samples were run 
in triplicate and the mean ± SD was recorded.  *p<.05 ,**p<.01 when 
compared to loading results for insulin loading in 1:1 MAA:EG. 
p<.05, p<.01 when 2KPI loaded samples are compared to  2KPI 
loaded in 1:1 MAA:EG 
 
 
Insulin 
Type 
P(MAA) 1:1MAA:EG g=1000 
3:1 MAA:EG 
g=1000 
3:1 MAA:EG 
g=2000 
Insulin 
 
21.04 ± 2.27** 82.36 ± 2.73 50.59 ± 5.82 53.53 ± 3.89 ** 
2K PI 99.73 ±1.46**, 61.24 ± 23.39 96.01 ± 5.58**, 100.74 ± 4.55**, 
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CHAPTER 8 
CONCLUSIONS 
 
Between 1900-1920, researchers discovered that extracts from the 
pancreas led to a decrease in glucose in diabetic patients, and by 1921, the 
removal of pancreases from the mixture by Banting and Best allowed human 
patients to be treated without a toxic effect.  Insulin was completely purified for 
the first time by J.B. Collup and shortly after that was standardized and scaled-up 
by Eli Lilly [1]. This discovery represents the biggest applied improvement in the 
treatment of diabetes to date. By the end of 1923, insulin was being shipped 
commercially. With this discovery, alongside the development of a tool to 
measure blood glucose levels, diabetic patients now had the opportunity to live 
comparatively normal, healthy lives.   
Since the development of fast-acting insulin in the early 1990ʼs, clinically 
useful improvements have been marginal.  An FDA-approved inhalable insulin 
product was developed, but as this product was withdrawn just 13 months after 
being placed on the market, the clinical usefulness is questionable [2, 3].   
Oral delivery is coined by many to be the “holy grail” of drug delivery due 
to the fact that it is versatile (due to the large number of drugs formulated in this 
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manner) and therefore familiar, easy to administer, and most importantly has 
good patient compliance [4, 5].  In diseases like diabetes, compliance is essential 
as hyperglycemia can cause a large number of severe acute and long-term 
effects, which may eventually lead to premature death. Additionally, for the 
treatment of chronic diseases, it is known that compliance improves dramatically 
with increased ease of use. 
A large number of technologies have been employed to enable the oral 
delivery of insulin, the most promising of which were developed in our laboratory 
[6].  P(MAA-g-EG) pH sensitive hydrogels represent the scientific  backbone of 
our solution;  these PEG-tethered hydrogels remain collapsed in the stomach 
where they protect the insulin from acid hydrolysis, and decomplex in the small 
intestine where the insulin is released. These hydrogels are mucoadhesive, and 
as such they improve the residence time of the insulin.   
The overall objective of this work was to improve the pharmacological 
availability through the covalent attachment of Poly(ethylene glycol) (PEG).  It 
was believed that the addition of this molecule would reduce degradation, 
increase circulation time, decrease antigenicity, improve drug stability, and 
increase solubility; ultimately yielding a more effective drug for oral delivery [7, 8].  
The first specific aim of this research was to select, optimize and 
characterize a high yield site-specific reaction for the preparation of PEGylated 
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insulin.  Previously published work on PEGylated insulin utilized a succinic 
propionic anhydride reaction for the PEGylation of insulin, however low yield and 
difficult purification prevented large-scale study.  Due to this fact, a nitrophenyl 
carbonate reaction scheme was developed for the PEGylation of insulin. The 
separation of protein from PEGylated protein was shown to be particularly difficult 
to achieve especially on the preparative scale [9].  The improved reaction yield 
made this significantly easier as there were significantly fewer unreacted 
components to remove.    The PEG-insulin conjugate was purified in bulk using 
centrifuge concentrators, as conventional dialysis cannot be used due to the 
tendency of PEG to adhere to the dialysis tubing; limiting further diffusion. 
The next objective of specific aim 1 was to determine the reaction site.  
This information was important to ensure that this site would not inhibit 
bioactivity.  Proving site-specificity would also improve the experimental 
homogeneity and therefore the repeatability of the experiments.  Initial mass 
spectrometry analysis yielded exciting preliminary results; the reaction occurred 
at 1:1 ratio suggesting that the reaction was in fact site-specific.  As the terminal 
amines of the dipeptide sequence were possible reaction sites, the standard 
analysis using Edmund degradation, which obtains the sequence from the N-
terminus, was ruled out due to the fact that two of the three possible reaction 
sites occurred on the N-terminus. Due to this fact, an alternate chemistry was 
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performed in which dithiothreitol was used to break disulfide bonds and 2-nitro-5-
thiocyanobenzoate was used to break cystenyl residues at the N-terminal side of 
the amine.  Individual peptides were separated with preparative HPLC and 
analyzed individually for molecular weight using MALDI-TOF MS, which led to the 
determination that the conjugation was occurring at the B29Lys position.  It was 
not expected that PEGylation at this location would alter bioactivity, as it has 
been shown that this sight does not participate in binding  [10].  
The second specific aim was to determine the cytocompatibility using 
fibroblasts and the transport properties of PEGylated insulin using a novel 
intestinal epithelium model. Cytocompatibility was evaluated using fibroblast 
cells, which were used because they exist in many body tissues. A reduction in 
cytocompability would suggest that the p-nitrophenol side reaction was not 
sufficiently removed from the reaction products, necessitating further purification, 
as neither PEG nor insulin had been shown to negatively affect 
cytocompatability. The results showed that a reduction in cytocompatability was 
only detected when cells were exposed to 1000 times more PEGylated insulin 
than would actually be seen by fibroblasts in a physiologic environment.  This led 
to the conclusion that the purification scheme could remove sufficient levels of p-
nitrophenol in order to be used in further study. 
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Next, the transport characteristics of the conjugate were determined.  A 
HT29-MTX/Caco-2 co-culture was used in this study as it was shown that this 
model was more physiologically accurate to in vivo conditions than the standard 
Caco-2 only culture.  This is due to the fact that HT29-MTX cells produce mucus, 
and in co-culture with Caco-2 cells, produce more accurate transepithelial 
resistance (TEER) conditions. TEER, which correlates to the strength of the tight 
junctions, is an important variable as it has been shown that hydrophilic drugs 
typically transport the cellular epithelium paracellurlarly  [11].  It was shown that 
incubation of PEGylated insulin in the presence of microparticles did not 
significantly alter the presence of tight junctions. The net transport was also 
evaluated by measuring the apical and basolateral concentrations over various 
time points using an enzyme-linked immunoassay.  It was also demonstrated that 
the transport of PEGyalated insulin was reduced in comparison to unconjugated 
insulin. 
The third specific aim was to determine the availability and in vitro 
intestinal transport properties of PEGylated insulin using a rat model.  This type 
of study limits the variables being studied primarily to degradation, 
mucoadhesion, and absorption.  
Before this study could be completed, the bioactivity of the PEGylated 
insulin conjugates was determined.  This was done by comparing the in vivo 
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response to subcutaneous injection of the insulin conjugates to insulin. The 
pharmacological availability was used to make this determination, because this 
directly measured the impact the drug conjugates had on the glucose level.  
Measuring the insulin concentration was less significant, and this would indicate 
absence or presence of insulin, rather than the action of the insulin on the blood 
glucose level.  This study showed that 1KPI had approximately the same 
pharmacological availability as insulin, 2KPI had approximately 41% of the 
pharmacological availability of insulin, and 5KPI had about 19%. 
The results from the closed loop intestinal assay demonstrated that 5KPI 
had a limited pharmacological availability, presumably because of the low 
pharmacological availability when delivered subcutaneously, in addition to its 
large size. The 1KPI performed similarly to insulin and did not have a significant 
effect on pharmacological availability.  Finally, the 2KPI outperformed insulin by 
6.8 times, with a pharmacologic availability of 3.65%, a significant improvement 
over unconjugated insulin.  It is believed this improvement occurred because that 
the 2K PEG chain is of sufficient length to prevent proteolytic degradation, yet 
short enough not to inhibit insulin-receptor binding. 
The fourth and final specific aim was to develop a P(MAA-g-EG) 
complexation hydrogel carrier for PEGylated Insulin. Using the conjugate that 
performed best in vivo, 2KPI, polymers were developed to optimize loading and 
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release characteristics in P(MAA-g-EG) hydrogels.  It was believed that PEG 
graft density would be the dominating force for determining loading and release 
behavior, and polymers were developed based on this theory.  The theory was 
proven to be correct, and P(MAA) particles without grafts had the best loading 
and release characteristics, while high graft density P(MAA-g-EG)  with a 1:1 
MAA:EG ratio had the poorest loading and release characteristics.  In order to 
obtain the protection from degradation and the mucoadhesiveness that the 
hydrogel provides, it was determined that some PEG grafting was necessary.   
Results showed that a hydrogel that had fewer, but longer grafts had better 
release characteristics than polymers that had a greater number of shorter grafts 
(both polymers had a 3:1 MAA:EG molar feed ratio).  As such, it was decided that 
a P(MAA-g-EG) hydrogel with a 3:1 MAA:EG ratio and a graft length of 2000 was 
the best polymer candidate studied. 
In brief, this work led to the following: 
1. A high-yield PEGylation reaction was developed that occurred at 
the B29Lys position of insulin, a site previously shown not to 
inhibit receptor binding. 
2. It was demonstrated that PEGylated insulin did not negatively affect 
cell tight-junctions or cytocompatability in the presence of 
P(MAA-g-EG) microparticles. 
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3. Orally delivered 2KPI improved pharmacological availability over 
unconjugated insulin by 6.8 times. 
4. The dominating mechanism for the loading and release of 
PEGylated insulin in P(MAA-g-EG) hydrogels was shown to be 
hydrogen-bonding.  It was also shown that a lower chain-density 
with longer chain length allowed for the best release 
characteristics for PEGylated insulin. 
Overall, these studies demonstrated that PEGylation of insulin at the B29Lys 
position with PEG (2000) significantly improves the current drug delivery system, 
presumably by preventing proteolytic degradation and increasing residence time 
in the blood [12]. 
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APPENDIX 
 
A1. Insulin PEGYlation with Nitrophenyl Carbonate 
1. Place shaker plate in incubator.  Preheat incubator to 37°C 
2. Weigh out 100 mg of insulin (human recombinant or bovine insulin)  
_________mg 
3. Add to 20 mL of PBS Ph 8 with EDTA 
4. Heat at 37°C in incubator until solution is clear 
5. Weigh out nitrophenyl carbonate PEG at a 1:5:1 molar ratio of NPC-
PEG:insulin  __________ mg  
**Note: be certain NPC-PEG is white, if it is yellow before use, it has been 
exposed to moisture. Discard. 
6. Slowly add NPC-PEG to solution. Scrape sides with spatula to ensure no 
NPC-PEG has adhered to the sides.   Solution will turn yellow. 
7. Place on shaker plate in 37°C incubator. React for at least 18 hours.  
Scrape sides periodically to ensure nothing has adhered. 
8. After 18 hours, dialyze against pH 7.4 PBS in refrigerator. Replace water 
every 12 hours until it is colorless. (Approximately 4 times). 
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9. Place solution in Vivaspin® 20 concentrator mwco 5000.  Centrifuge at 
3,000-10,000 g for 30 minutes.  Discard filtrate in bottom of test tube.  Add 
approximately 10 mL PBS to concentrator.  Aspirate 20 times.   
10.  Repeat step 9 three additional times.  The final time, do not add additional 
PBS. 
11. Add 25μL to HPLC vial.  Dilute to 0.2 mL.  Run through HPLC and 
determine % PEGylated. 
12.   Place solution in glass test tube.  Dry with centrifuge vacuum drier.  Do 
not lyophilize, as this will denature protein. 
13. Store at -15°C with desiccant until use. 
** Only use glassware that has been used exclusively for bio reactions. If 
polymerization or other reaction has occurred in vessel, the sample may become 
contaminated. 
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A.2. Polymer Recipes 
1:1 MAA:EG PEG-1000 
  MW Density Mole Wt(g) 
MAA 86.00 1.0150 0.04127 3.54950 
PEGMMA-1000 1100.00 1.0790 0.00182 2.00000 
TEGDMA (1 mol% of total monomer) 330.00 1.0750 0.00043 0.14220 
Irgacure®184 (1 wt% of total monomer) 184.00   0.05550 
Water 18.00 0.9950  2.77470 
Ethanol 46.00 0.7890  2.77470 
Total Monomer   0.0431 5.5495 
Total Weight    11.2966 
 
 
 
3:1 MAA:EG PEG-1000 
 MW Density Mole Wt(g) 
MAA 86.00 1.015 0.06191 5.32383 
PEGMMA-1000 1100.00 1.079 0.00048 1.00100 
TEGDMA (1 mol% of total monomer) 330.00 1.075 0.00062 0.20587 
Irgacure®184 (1 wt% of total monomer) 184.00   0.06325 
Water 18.00 0.995  3.16240 
Ethanol 46.00 0.789  3.16240 
Total Monomer   0.0623 6.32483 
Total Weight    12.9187 
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3:1 MAA:EG PEG-2000 
 MW Density Mole Wt(g) 
MAA 86.00 1.015 0.06191 5.32383 
PEGMMA-2000 in 50wt% water 2080.00 1.079 0.00048 2.00200 
TEGDMA (1 mol% of total monomer) 330.00 1.075 0.00062 0.20587 
Irgacure®184 (1 wt% of total monomer) 184.00   0.06324 
Water 18.00 0.995  2.16140 
Ethanol 46.00 0.789  3.16240 
Total Monomer   0.0623 7.32400 
Total Weight    12.9169 
 
P(MAA) (no PEG grafts) 
  MW Density Mole Wt(g) 
MAA 86.00 1.015 0.0581 5.000 
TEGDMA (1 mol% of total monomer) 330.00 1.075 0.0006 0.192 
Irgacure®184 (1 wt% of total monomer) 184.00   0.050 
Water 18.00 0.995  2.500 
Ethanol 46.00 0.789  2.500 
Total Monomer   0.05815 5.000 
Total Weight    10.242 
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A.3. Matrix Assisted Laser Desorption/Ionization- Time of Flight Mass 
Spectrometry Protocol 
1. Prepare a 2% formic acid in water solution 
2. Prepare matrix solution: add 10 mg/mL α-cyano-4-hydroxycinnamic acid to 
2% formic acid solution.  Heat and sonicate to solubulize 
3. Spot 0.5 μL sample of matrix solution on a steel sample plate.    
4. Spot 0.5 μL of sample of protein, three times over the matrix solution and 
allowed to dry.  *Can be dried with blow-dryer to hasten drying. 
5. Once dry, if the spot appears amorphous, add a 0.5 μL sample of 2% 
formic acid and allowed to dry.   
6. Analyze with MALDI-TOF spectrometry under vacuum with a laser 
intensity of 300-500 nm. 
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A.4. PEGylated Insulin Loading Protocol 
1. Sigmacote® 12- 50 mL beakers and 1- 250 mL beakers.  Air dry in hood 
overnight and rinse with water before use 
2. Make 250 mL of PEG-insulin or insulin stock solution. 
a. For insulin: make 250 mL of stock solution with concentration 
0.5mg/mL (8.61 * 10-5 mols/mL) insulin 
i. Dissolve 125 mg of insulin in 62.5 mL 0.1 N HCL 
   _________mg 
ii. Add 150 mL pH 7.4 PBS 
iii. Normalize pH with 62.5 mL of 0.1 N NaOH 
b. For PEG insulin: 
i. Dissolve molar equivalent of PEGylated insulin (8.61 * 10-5 
mols/mL) directly into 250 mL pH 7.4 PBS 
3. Weigh 140 mg of each polymer three times. 
 
 1:1 MAA:EG 3:1 MAA:EG 
PEG 1000 
3:1 MAA:EG 
PEG 2000 
MAA  
Sample 1 mg mg mg mg 
Sample 2 mg mg mg mg 
Sample 3 mg mg mg mg 
 
4. Add 20 mL stock solution to each beaker.  Take a 200 μL sample from 
each beaker before adding the polymer (Sample A).  Filter with 0.2 μL 
PVDF filter.  Replace volume with PBS. 
5. Slowly add each polymer sample to solution under constant stirring. 
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6. Stir for 2 hours and then stop.  Allow polymers to settle before taking 
200μL sample. Replace volume with PBS (Sample B). 
7. Add 10 mL 0.1 N HCL.  Incubate with acid for 30 minutes.  Take 200 μL 
sample. 
8. Scrape particles off walls of beaker with spatula.  Pour into vacuum filter.  
Rinse beaker with 5 mL deionized water three times to ensure all particles 
are collected and to wash particles. 
9. Freeze at -80°F.  Lyophilize.  Store at -15°C until use. 
10. Prepare serial dilutions for standards.  (0.5 mg/mL, 0.25 mg/mL, 0.125 
mg/mL 0.0625 mg/mL, 0.03125 mg/mL) 
11. Load HPLC samples.  As PEGylated insulin has a significantly wider 
polydispersity than peptides and proteins, run each sample twice and take 
average.  Run standards at the beginning and the end of the run. 
12. Once all samples have been run on HPLC, alternate di water and pH 7.4 
buffer until baseline is unchanging.  Run shutdown procedures 
(proteinshutdown2). 
 
** Note that PEG has a tendency to adhere to the column. Start with the 
lowest expected concentration to limit contamination of the following sample. 
At least every five samples, run di water, pH 7.4 buffer and another di water 
sample to remove any residual PEGylated insulin in the column. 
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A.5. Release Protocol 
1. Sigmacote®  4 vessels and allow to dry overnight in the fume hood.  Rinse 
thoroughly with water before use. 
2. Fill and preheat Distek dissolution apparatus to 37°C 
3. Weigh out 10 mg polymer samples: 
4. Sample 1:_____ mg   Sample 2:_____mg  Sample 3:______mg 
5. Fill each vessel with 20 mL of pH 7.4 PBS 
6. Set Distek to 100 RPM 
7. Slowly add 10 mg to three of the vessels, ensuring that particles do not 
aggregate.   
8. Take 200 μL samples at 0, 5, 10, 15, 30, 60, and 120 minutes.  Replace 
volume with PBS buffer. 
9. Prepare serial dilutions for standards.  (0.5 mg/mL, 0.25 mg/mL, 0.125 
mg/mL 0.0625 mg/mL, 0.03125 mg/mL). 
10. Load HPLC samples.  As PEGylated insulin has a significantly wider 
polydispersity than peptides and proteins, run each sample twice and take 
the average.  Run standards at the beginning and the end of the run. 
11.  Once all samples have been run, alternate deionized water and pH 7.4 
buffer until spectra is completely level.  Then follow shutdown procedures. 
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A.6. NHS-Cye7™ Insulin Conjugation 
1. Prepare solution A: add 0.1 g of ethylenediaminetetraacetic acid (EDTA) 
to 50 mL PBS. As pH will drop, adjust with NaOH back to 7.4.  
2. Dissolve 12.5 mg insulin in 2.5 mL of Solution A. 
3. Prepare a desalting column. Pour off storage solution and prime column 
by washing it five times with the 50 mM NaHCO3 buffer (pH 7.9).  Note that 
the pKa of A1GLY and B1PHE is 7.5-8, which is why this pH was selected 
for the buffer.   
4. Remove PBS salts and EDTA with desalting column.  Pour 2.5 mL of 
Solution B into column and allow the entire solution to equilibrate (cap the 
bottom and let the entire solution soak into the Sephadex® beads).  Uncap 
and let liquid run off. 
5. Add 2.5 mL NaHCO3 buffer and collect fractions (10 drops/test tube).  
Repeat 3 times. 
6. Determine the presence of Insulin in corresponding fractions using the 
Lowry Method for protein analysis.  Combine insulin-containing fractions to 
make Solution B. 
7. Dissolve 125 µL of NHS-Cy7™ in DMSO. 
8. Solution B (~1.8mL) was added to Solution C and reacted in the dark at 
RT for 14 hours on a rotary plate (Solution D).  
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9. Add 15 µL of Triethyleneamine (TEA) to Solution D and react on a rotary 
plate in the dark at RT for 30 minutes. 
10. Dialyze solution D against PBS and exchange PBS every 6 hours until 
colorless.  (Note that the reaction efficiency was high and very little NHS-
Cy7™ was found in the dialysate). 
11. Freeze the solution and lyophalize. 
12. When dry, store Cy7™-insulin in refrigerator in the dark until use. Use 
within 7 days. 
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A.7. Abbreviations 
1KPI    PEG(1000)-insulin 
2KPI    PEG(2000)-insulin 
5KPI    PEG(5000)-insulin 
BSA    bovine serum albumin 
Caco-2   human colorectal adenocarcinoma cells 
DMEM   Dulbeccoʼs modified eagles medium 
EDTA    ethylenediaminetetraacetic acid 
FBS    fetal bovine serum 
HBSS    Hankʼs balanced salt solution 
HPLC    high-pressure liquid chromatography 
HT29-MTX human caucasion colon adenomacarcinoma cells 
grade II adapted to 10-6 M methotrexate 
MAA    methacrylic acid 
MALDI-TOF MS matrix assisted laser desorption/ionization-time of 
flight mass spectrometry 
NIH/3T3   murine embryonic fibroblasts 
NPC-PEG   nitrophenyl carbonate- poly(ethylene glycol) 
PBS    phosphate buffered saline 
PEG    poly(ethylene glycol) 
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PEGMMA poly(ethylene glyocol) monomethyl ether 
monomethacrylate 
P(MAA-g-EG)  Poly(methacrylicacid-grafted-ethylene glycol) 
t-boc     di-tert-butyl bicarbonate  
TEER    transepithelial resistance 
TEGDMA   tetraethylene glycol dimethacrylate 
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